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IV. ABSTRACT 
The human metapneumovirus is a novel paramyxovirus associated with acute 
respiratory infections in children, adults, elderly and immunocompromised 
individuals. It has a worldwide distribution and the prevalence range between 
1.5% to 25% in individuals with respiratory infections. Based on phylogenetic 
analysis 2 distinct genetic groups (A and B) that are sub-divided into four 
subgroups (A1, A2, B1 and B2) have been shown to circulate. Until recently, 
there was no information on the molecular epidemiology and the clinical 
characteristics of the hMPV in Africa, including South Africa, a region with a 
high prevalence of paediatric human immunodeficiency virus type-1 (HIV) 
infection.  
 
The molecular epidemiology and clinical characteristics of the hMPV in South 
Africa was investigated over a three period (2000-2002) in children 
hospitalized with lower respiratory tract infection. The children were part of a 
cohort participating in a phase 3 clinical trial investigating the efficacy of a 9-
valent-pneumocococcal protein-polysaccharide conjugate vaccine (PCV).  
The objectives of the study were: i. to investigate the molecular epidemiology 
of hMPV in South Africa; ii. characterize the burden of hMPV disease and 
determine the clinical features of hMPV-LRTI in children infected and not 
infected by HIV; iii. probe the role of Streptococcus pneumoniae in the 
pathogenesis of hMPV-LRTI.  
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The overall prevalence of hMPV in children hospitalized with lower respiratory 
tract infections (LRTI) was 7.4%. The mean age of children with hMPV 
associated LRTI (hMPV-LRTI) in South Africa was 13.3 months (range 1.4-
49.2 months), with HIV infected children being older than children not infected 
with HIV (mean [range] 17.6 [4.5-44.3] vs. 12.3 [1.4-49.2] months; P=0.007). 
The incidence of hMPV-LRTI was 5.0 (95%C.I.3.3-7.5) fold greater in HIV 
infected children (incidence rate: 2 504 [95%C.I. 1 683-3 577] per 100 000) 
than in HIV uninfected children (incidence rate: 505 [95%C.I. 409-618] per 
100 000, P<0.0001). Human metapneumovirus was identified less frequently 
than RSV but more commonly than other studied respiratory viruses.  
The double-blind PCV-9 vs. placebo controlled trial was used to probe the role 
of pneumococcal co-infections contributing to the pathogenesis of severe 
hMPV-LRTI. The incidence of hospitalization for hMPV-LRTI was reduced by 
46% (95%, CI, 25-63; P=0.0002) in PCV-9 vaccinees compared to placebo 
recipients. This inferred that coinfection with Streptococcus pneumoniae was 
integral to the pathogenesis of hMPV-LRTI requiring hospitalization.  
 
Both groups of the hMPV circulated during the three year period including 
concurrent circulation of multiple subtypes of the virus. There was a transition 
from group B to group A subtype virus as the dominant circulating virus over 
sequential years.  
 
Sequence analysis of the two attachment glycoproteins (F and G), showed the 
F gene protein to be highly conserved, in contrast the attachment protein gene 
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(G protein) was highly variable particularly in the extracellular domain between 
lineages. Repeat hMPV-LRTI by either homologous or heterologous strains 
within 3 months of each other suggested that natural infection did not confer 
complete immunity to hMPV. 
 
The present study demonstrated that hMPV is a leading pathogen associated 
with LRTI among children in Africa and indicated that occult pneumococcal 
co-infections’ were integral in the pathogenesis of hMPV-LRTI requiring 
hospitalization. Additionally, this is the first study to have characterized the 
molecular epidemiology of hMPV in Africa and provides insight as to issues 
that may exist regarding the design of an hMPV vaccine. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Introduction 
The Global Burden of Disease (GBD) study reported that acute respiratory 
infections together with measles, diarrhea, malaria and HIV/AIDS accounted 
for more the 50% of deaths in children in 2001 (Lopez et al., 2006). Lower 
respiratory tract infections are among the leading causes of death in the low-
middle income and high-income countries and rank third and fourth 
respectively (Lopez et al., 2006). Compared to the 1990 statistics there was 
less of a decline in death rates due to acute respiratory infections in South 
Asia and sub-Saharan Africa than other areas (Lopez et al., 2006). 
 
Viruses are the most common pathogens identified in infants and young 
children with a lower respiratory tract infection (LRTI). It is estimated that 
approximately 3% of children under 1 year of age are hospitalized with severe 
viral lower respiratory tract infections in the USA (van Woensel et al., 2003). In 
South Africa viruses were identified from 30% of children hospitalized with 
severe lower respiratory tract infections (Madhi et al., 2000) . 
 
Several viruses have been shown to cause LRTI in children of which 
respiratory syncytial virus (RSV) is the most common cause (van Woensel et 
al., 2003). 
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In England RSV is responsible for 75% of hospital admission in children under 
5 years with bronchiolitis (van Woensel et al., 2003) and in South Africa RSV 
was the dominant (49.7%) respiratory viral pathogen among children not 
infected by HIV that were hospitalized for LRTI (Madhi et al., 2000). 
 
Recently a novel respiratory virus, named human metapneumovirus (hMPV), 
was isolated in the Netherlands (van den Hoogen et al., 2001). Based on the 
genome constellation and morphological features it has been classified into 
the family, Paramyxoviridae (van den Hoogen et al., 2001), subfamily 
Pneumovirinae and genus, Metapneumovirus. It is the only known species 
from this genus that infects humans and prior to its identification the only other 
known species of the Metapneumovirus genus was the avian pneumovirus 
(APV). 
 
Human metapneumovirus was initially isolated from 28 children with 
respiratory tract infections from samples collected over a 20 year period (van 
den Hoogen et al., 2001) and was identified in 10% of samples from children 
with respiratory tract infections in which no other pathogen was detected (van 
den Hoogen et al., 2001).  
 
Serological data provided evidence of infection by hMPV to be present since 
1958 among individuals across different age-groups, (van den Hoogen et al., 
2001) with almost all children having been infected by 5-10 years of age in the 
Netherlands, Japan and Ethiopian children (Ebihara et al., 2003; van den 
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Hoogen et al., 2001; Wolf et al., 2003). In South Africa a study reported an 
overall seroprevalence rate of 63.5% among children aged from 0 to 36 
months, with the highest seroprevalence rate of 92% observed among 
children age 24-36 months (IJpma et al., 2004). 
 
Following the initial identification of hMPV, it has been associated worldwide 
as an etiological agent of upper respiratory tract infections (URTI), LTRI, acute 
wheezing, asthma exacerbation as well as otitis media (Hamelin et al., 2004; 
van den Hoogen et al., 2004b). Human metapneumovirus has been identified 
as a pathogen associated with respiratory tract infections across all age-
groups as well as among immunocompromised individuals. It is however most 
prevalent in children younger than 2 years of age with respiratory illness 
(Maggi et al., 2003; Viazov et al., 2003) and has been detected in children as 
young as 3-4 months of age (Peiris et al., 2003; van den Hoogen et al., 2003). 
 
1.2. The human metapneumovirus structure 
The hMPV is an enveloped, negative sense RNA virus, with pleomorphic 
spherical or filamentous virions (Peret et al., 2002; van den Hoogen et al., 
2001) with characteristics which are similar to other Pneumoviruses (Easton 
et al., 2004). 
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1.2.1. Genome structure 
The genome of the hMPV is approximately 13kb with 93.8% of the genome 
involved in open reading frames (ORFs) that are separated by short non-
coding regions. Most of the ORFs are initiated at nucleotide (nt) 14 of its 
mRNA and terminate within a gene-end signal (termination sequence). This 
stop-restart process that guides transcription is characteristic of viruses that 
belong to the order Mononegavirus (Biacchesi et al., 2003).  
 
The genome encodes 8 mRNAs and is organized as follows: 3’-N-P-M-F-M2-
SH-G-L-5’ (Biacchesi et al., 2003; van den Hoogen et al., 2002) flanked at the 
3’ end by a leader sequence and the 5’ by a trailer sequence. These proteins 
are common to members of the subfamily, Pneumovirinae, however, the 
genomic organization is similar to avian pneumovirus (APV) (Biacchesi et al., 
2003; van den Hoogen et al., 2002; van den Hoogen et al., 2001).  
 
Based on comparisons to the ORFs of APV and RSV, the hMPV proteins are 
as follows: N= nucleocapsid RNA binding protein, P (phosphoprotein), M (non 
glycosylated matrix protein), F (fusion glycoprotein), M2-1 (transcription 
elongation factor), M2-2 (RNA synthesis regulatory factor), SH (small 
hydrophobic surface protein), G (attachment protein) and L (polymerase 
subunit).  
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1.2.1.1 The nucleoprotein (N gene) 
The nucleoprotein forms an integral part of the nucleocapsid of the virion and 
is tightly associated to the RNA genome and gives the RNA genome its helical 
structure (Easton et al, 2004). The N gene of the hMPV encodes a 394 amino 
acid protein and shares a 88% amino acid sequence identity with APV-C 
(Biacchesi et al., 2003; van den Hoogen et al., 2002) and 41% amino acid 
identity with RSV. Three conserved regions (between amino acids 160-172; 
251-263 and 278-327) in the N protein present among members of the family 
Paramyxoviridae were also present in hMPV (van den Hoogen et al., 2002). 
 
1.2.1.2 The phosphoprotein (P gene) 
Phosphoproteins of pneumoviruses are associated with the RNA genome and 
form part of the nucleocapsid and are believed to be involved in both 
replication and transcription (Easton et al., 2004). hMPV putative 
phosphoprotein contains one ORF of 294 amino acid that lacks cysteine 
residues and has a glutamate rich C terminus (van den Hoogen et al., 2002). 
Its proteome shares 68% identity with the APV-C proteome and similar to 
other pneumoviruses also has the highly conserved region between amino 
acid 185-241, thought to be involved in RNA synthesis or maintaining the 
structure of the nucleocapsid (van den Hoogen et al., 2002). 
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1.2.1.3 The matrix (M) protein 
Matrix proteins lines the inner surface of the lipid membrane that surrounds 
the core and forms a link between the nucleocapsid and the envelope 
inactivating the nucleocapsid of pneumoviruses prior to packaging (Easton et 
al., 2004). Human metapneumovirus M ORF codes a 254 amino acid protein 
with high amino acid identity to the M protein of APV. Similar to other 
members (RSV, APV and PVM) of the subfamily Pneumovirinae, two 
secondary ORF, one (54 amino acids) within and the other (33 amino acids) 
overlapping the major ORF was identified (van den Hoogen et al., 2002), 
however there have been no reports on proteins synthesized by these 
secondary ORF (van den Hoogen et al., 2002). The conserved hexapeptide 
(YTAAVQ) at residues 14-19 present in other pneumoviruses was also 
present in the putative hMPV M protein. 
 
1.2.1.4 The 22 K (M2) proteins 
The genes encoding the M2 proteins of metapneumoviruses contain two 
overlapping ORFs M2-1 and M2-2 (Easton et al., 2004). The M2-1 is involved 
in virus RNA synthesis, functioning as a transcription elongation factor 
(Easton et al., 2004). The M2-1 of hMPV encodes a 187 aa protein and 
reveals a 84% identity with M2-1 of APV (van den Hoogen et al., 2002). The 
putative M2-2 ORF is 77 aa in length and starts at nt 512 in the M2-1 (van den 
Hoogen et al., 2002) 
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1.2.1.5 The fusion (F) protein 
Fusion (F) proteins of the family Paramyxoviridae show limited identity to each 
other but are structurally similar. They are synthesized as inactive precursors 
(F0) and are cleaved by the host cell proteases generating two subunits, an 
N-terminal F2 and a larger C-terminal F1 subunit. The activated fusion protein 
is responsible for the fusion of the viral membrane and the host cell plasma 
membrane in combination with the attachment protein (Easton et al., 2004; 
Morrison, 2003). In a study using recombinant hMPV that lack SH and G 
proteins showed that the F protein may be used as sole surface protein for 
replication in vivo (Biacchesi et al., 2004b). 
 
The F gene of hMPV encodes a 539 amino acid protein that has 81% identity 
to the F protein of APV (van den Hoogen et al., 2002). Structurally it is similar 
to other members of the family Paramyxoviridae. The F protein of hMPV is 
glycosylated containing three potential N glycosylation sites. Fourteen 
cysteine residues, 12 of which are located in the F1 subunit and 2 in the F2 
subunit are present in the ORF and 8 are conserved among all 
paramyxoviruses. 
 
Unlike RSV that contains two cleavage sites, the hMPV F protein contains 
only one cleavage site, containing the residues RQSR. The primary sequence 
of the hMPV F protein contains 3 hydrophobic domains: i. the signal peptide 
located at the amino terminus of the F2 subunit; ii. a fusion and membrane 
anchor domains located in the F1 subunit at N; and iii. C termini respectively 
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(van den Hoogen et al., 2002). The fusion domain is thought to initiate fusion 
in paramyxoviruses, by inserting into the target membrane (Morrison, 2003). 
Also present in F protein of hMPV are two heptad repeat domains (HRA and 
HRB) that are believed to be essential for viral fusion. Both of these domains 
are located in the F1 subunit, with HRA located adjacent to the fusion domain 
and HRB adjacent to the membrane anchor domain at the carboxy terminal.  
 
The F protein gene of the hMPV is believed to be the major antigenic 
determinant that mediates extensive cross-lineage neutralization and 
protection (MacPhail et al., 2004; Skiadopoulos et al., 2006; Skiadopoulos et 
al., 2004). Sequencing of the F gene protein have shown it to be highly 
conserved between strains (Bastien et al., 2003a; Bastien et al., 2003b; 
Biacchesi et al., 2003; Boivin et al., 2004; Ishiguro et al., 2004; van den 
Hoogen et al., 2002; van den Hoogen et al., 2004a). Amino acid alignments of 
the predicted F ORF has revealed the presence of several conserved cysteine 
residues between groups as well as lineages and the presence of specific 
substitutions that act as signature sequences to differentiate hMPV groups 
(Boivin et al., 2004; van den Hoogen et al., 2004a). Some of these 
substitutions were present in functional domains such as at codon 122 in the 
fusion domain and codons 135 and 143 in the heptad repeat A region (Boivin 
et al., 2004). 
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1.2.1.6 The small hydrophobic (SH) protein 
The precise function of the SH protein is not known and RSV mutants lacking 
small hydrophobic protein have shown that it is not necessary for attachment, 
infectivity or virion assembly, but has been shown to impair a host response 
(Easton et al., 2004). Recombinant hMPV lacking SH have been shown to 
replicate efficiently in culture suggesting that the SH is not essential for growth 
in cell culture and when administered to hamsters replicated in upper and 
lower respiratory tracts (Biacchesi et al., 2004b). Recently it was shown in 
hamsters that SH may not be a protective antigen (Skiadopoulos et al., 2006). 
 
Human metapneumovirus SH ORF is the largest and encodes a 183 amino 
acid protein with a low sequence identity to other pneumoviruses. Despite this 
low amino acid identity, its amino acid composition is relatively similar to APV 
and RSV with high percentages of serine and threonine residues (Biacchesi et 
al., 2003; van den Hoogen et al., 2002). The SH protein of hMPV is a type II 
glycoprotein with a cytoplasmic amino terminus and extracellular carboxy-
terminus. The protein is anchored to the plasma membrane by a hydrophobic 
signal-anchor sequence at the amino terminus. The extracellular domain has 
2-4 N linked and 2-3 potential O glycosylation sites, and 9-10 cysteine 
residues (Biacchesi et al., 2003; Biacchesi et al., 2004a; van den Hoogen et 
al., 2002). 
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1.2.1.7 The attachment glycoprotein (G)  
Members of the Paramyxoviridae family encode two surface glycoproteins, a 
fusion protein as well as an attachment protein that participates in viral 
attachment. Depending on the genus of the virus the attachment protein may 
be hemagglutinin-neuraminidase (HN), hemagglutinin (H) or glycoprotein (G 
protein) (Morrison, 2001). Members of the subfamily Pneumovirinae encode 
the G protein, a type II mucin-like glycoprotein.  
 
The putative hMPV G ORF is located adjacent to the SH gene and depending 
on the strain encode a 217-236 amino acid protein (Biacchesi et al., 2003; 
Peret et al., 2004; van den Hoogen et al., 2002). The predicted hMPV G 
protein has features consistent with an anchored type II mucin like 
transmembrane protein as seen for other pneumoviruses (RSV and APV). 
Consistent with mucin like glycoproteins, the G protein is highly glycosylated 
as predicted by the high serine-threonine content and in addition has a high 
proline content (Biacchesi et al., 2003; Peret et al., 2004; van den Hoogen et 
al., 2002). Hydrophilic profiles revealed an anchored type II transmembrane 
protein pattern with an intracellular amino terminus that is hydrophilic followed 
by a short hydrophobic region of approximately 20 amino acids and a mostly 
hydrophilic extracellular carboxy terminal (Peret et al., 2004; van den Hoogen 
et al., 2002) 
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Despite the similar features the predicted hMPV protein has with other 
pneumoviruses it shows no identities with RSV or APV (van den Hoogen et 
al., 2002) and lacks some prominent features of RSV. Compared to the RSV 
the hMPV G protein lacks the second methionyl translational start codon that 
is necessary for the translation of the soluble secreted form of RSV G protein. 
The hMPV G protein contains between 1-2 cysteines residues of which one is 
conserved in the extracellular domain, unlike RSV that contains 4 conserved 
closely spaced cysteines that overlap with 13 conserved amino acids to form 
a cystine noose and include an CX3C chemokine motif (Biacchesi et al., 
2003).  
 
1.2.1.8 The polymerase protein (L) 
The L protein is the major component of the viral RNA-dependent RNA 
polymerase complex (Easton et al., 2004; van den Hoogen et al., 2002). It is a 
large protein an the hMPV L ORF encodes a 2005 aa protein (van den 
Hoogen et al., 2002). It shares the highest homology with APV (64%) and the 
4 core polymerase motifs that may be essential for polymerase function are 
well conserved in hMPV L protein (van den Hoogen et al., 2002). 
 
1.3 Molecular epidemiology of the hMPV 
The molecular epidemiology of hMPV is starting to unfold as studies have 
shown substantial genetic variability between strains particularly in the surface 
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attachment glycoprotein. It is this variability that may be responsible for the 
ability of hMPV to cause seasonal epidemics and reinfections. 
 
van den Hoogen et al. performed phylogenetic analysis on partial nucleotide 
sequences of the N, M, F and L ORFs and showed the existence of 2 distinct 
genetic groups, A and B; (van den Hoogen et al., 2001). The existence of 
these genetic groups have been confirmed by other phylogenetic studies and 
within these groups, two subgroups have been identified (type 1 and 2) 
(Bastien et al., 2003a; Bastien et al., 2003b; Biacchesi et al., 2003; Boivin et 
al., 2002; Ebihara et al., 2004b; Ishiguro et al., 2004; Maggi et al., 2003; Peret 
et al., 2002; Viazov et al., 2003). 
 
Genetic distances have also provided support for the existence of the two 
genetic groups. Sequence analysis of the genomes of strains from genetic 
groups A and B from the Netherlands (van den Hoogen et al., 2002) Canada 
(Biacchesi et al., 2003) and Japan (Ishiguro et al., 2004) showed an overall  
80% nucleotide identity between groups A and B (Biacchesi et al., 2003; 
Ishiguro et al., 2004). There was a high degree of identity within subgroups for 
all ORFs compared by Biacchesi et al. and Ishiguro et al. (Biacchesi et al., 
2003; Ishiguro et al., 2004) 
  
1.3.1 Genetic variation in the surface glycoproteins 
Reverse transcription polymerase chain reaction (RT-PCR) and nucleotide 
sequencing has been used to examine the variability of hMPV for molecular 
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epidemiology studies. Several studies have examined the degree of variation 
between clinical strains for the surface glycoproteins (F and G gene proteins).  
 
Nucleotide and amino acid identities between genetic groups based on the 
partial and full length sequences of the F gene showed a low degree of 
variability between groups, ranging from 81-85% at the nucleotide level and 
95% at the amino acid level (Bastien et al., 2003a; Bastien et al., 2003b; 
Biacchesi et al., 2003; Boivin et al., 2004; Ishiguro et al., 2004; van den 
Hoogen et al., 2002; van den Hoogen et al., 2004a).  
 
In contrast, there was a high degree of variability at the nucleotide and amino 
acid level for the attachment glycoprotein. Sequence diversity between group 
A and B clinical isolates of hMPV were between 50-57% at nucleotide level 
and 30-37% amino acid level in the Netherlands (van den Hoogen et al., 
2004a), 52-58% at nt level and 31-38% at amino acid level in Canada (Peret 
et al., 2004) and 56-60% at nt level and 31-35% at amino acid level in Japan 
(Ishiguro et al., 2004).  
 
Within groups higher percentage difference in identities were observed at the 
nt level (74-100%) compared to the amino acid level (61-100%) (Ishiguro et 
al., 2004; Peret et al., 2004; van den Hoogen et al., 2004a).  
Different lengths of ORFs were also reported between groups. Group A ORFs 
ranged between 217-235 polypeptides and groups B ORF between 220-236 
polypeptides (Ishiguro et al., 2004; Peret et al., 2004; van den Hoogen et al., 
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2004a) and are due to either nucleotide substitutions, use of alternative 
transcription codons or insertions (Ishiguro et al., 2004; Peret et al., 2004; van 
den Hoogen et al., 2004a). Most of the variation observed in the G protein 
was in the extracellular domain with the intracellular and transmembrane 
domains being conserved. 
 
From these studies conducted on hMPV strains isolated from countries in the 
northern hemisphere the variation may be due to host immunity and extensive 
glycosylation may reduce its antigenicity by shielding the virus protein with 
host specific sugars as has been suggested for RSV (Easton et al., 2004). 
 
1.4 Diagnosis of the human metapneumovirus 
The use of rapid sensitive diagnostic methods for detection of respiratory 
viruses is essential. hMPV was originally cultured on tertiary monkey kidney 
(tMK) cells in the unusual presence of trypsin and induced a cytopathic effect 
postinfection (van den Hoogen et al., 2001). Subsequently it has been shown 
to induce cytopathic effects on LLC-tMK2 cell and Vero cells (Hamelin et al., 
2004; van den Hoogen et al., 2004a) and can grow efficiently on Hep-2 cells 
without inducing a cytopathic effect (Chan et al., 2003). The advantage of viral 
culture is that it will allow for the detection of unknown hMPV lineages, 
however, the standard culture procedures are difficult and laborious.  
The use of monoclonal antibodies (MAbs) for the diagnosis of hMPV has been 
performed (Percivalle et al., 2005), is rapid and may provide a result within 2 
hours after NPA collection (Gerna et al., 2006). The use of MAbs was recently 
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shown to be less sensitive than molecular approach using RT-PCR, detecting 
only about 1/3 of the samples positive by RT-PCR (Gerna et al., 2006). 
Further, as mentioned, by 5-10 years of age all individuals are exposed to 
hMPV. Therefore serological assays for the diagnosis of current hMPV 
infections are limited and would require acute and convalescent samples, thus 
being of limited clinical value.  
 
Reserve transcriptase polymerase chain reaction (RT-PCR) is the current 
method of choice for the diagnosis of hMPV. Primers sequences from several 
genes (L, N, F) based on the sequence of the prototype strain from the 
Netherlands (NL/01/00) have been designed and used for the detection of 
hMPV, however there is concern that the genetic variability displayed by some 
genes of hMPV may underestimate its prevalence (Hamelin et al., 2004) and 
certain primers pairs may not detect both lineages of hMPV (Sarasini et al., 
2006; van den Hoogen et al., 2003). Therefore if RT-PCR is used, the primers 
should be able to detect both genetic groups of the hMPV with good specificity 
and sensitivity. 
 
Recently the sensitive and rapid real RT-PCR assay which employs the use of 
fluorescent labeled probes has been used for the detection of hMPV (Boivin et 
al., 2003; Cote et al., 2003; Kuypers et al., 2005; Mackay et al., 2003; 
Maertzdorf et al., 2004). This technology may be best suited for diagnosis as 
carefully designed probes may be used to detect the different lineages of the 
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virus, it does however, require the use expensive equipment that may not be 
readily available in all laboratories, particularly in developing countries.  
 
Although PCR may be the goal standard for diagnosing infections, its 
sensitivity may be a limitation for as it may detect an infection that is currently 
not causing illness. Further, factors such as degradation of RNA during 
specimen transport or the stage of patients illness which cannot be controlled 
for may results in false negatives (Kuypers et al., 2005). 
 
1.5 Clinical epidemiology of hMPV 
The hMPV has been identified as the causative pathogen in a substantial 
proportion of lower respiratory tract infections in young children. Although the 
mean age of hMPV-associated LRTI is greater than for RSV-LRTI the clinical 
symptoms of hMPV are indistinguishable from RSV and hMPV is second only 
to RSV as the cause of bronchiolitis in children (Kahn, 2006). 
 
The prevalence of hMPV has been reported worldwide with a range as low as 
1.3% to infection rates as high as 43% in individuals with respiratory tract 
infections (Table 1.1). Differences in the reported prevalence may be related 
to differences in the study design and study population between studies. Most 
of the studies investigated the prevalence of hMPV in hospitalized children; 
however some studies included all patients enrolled whereas others limited 
their investigation to samples that were negative for other respiratory viruses. 
Other factors that may impact on the reported prevalence are i) some studies 
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were limited to respiratory season, ii) the different ages of children for whom 
the hMPV was investigated and iii) the diagnostic methodology used (viral 
culture, RT-PCR, serology) differed between studies.  
 
In addition the frequency of hMPV in the general community has also been 
reported with differing results. A study conducted in the United Kingdom 
identified the hMPV in 1.3% of patients with influenza-like illness (ILI) in the 
(Stockton et al., 2002), in Canada 2.9% of all respiratory tract infections in the 
community were due to hMPV (Boivin et al., 2003). The differences in 
prevalence of hMPV between the above two studies may be due to the study 
in the United Kingdom being restricted to patients with influenza-like illness.  
In Germany the prevalence of the hMPV in the general community was 1% in 
children <3 years of age with LRTI who were negative for other known 
respiratory pathogens (Konig et al., 2004). 
 
Lung disease, premature birth, underlying heart disease and a compromised 
immune system are risk factors for severe hMPV disease (Beckham et al., 
2005; Dollner et al., 2004; Kahn, 2006; Ulloa-Gutierrez et al., 2004). Human 
metapneumovirus has been identified in an immunocompromised child with 
acute lymphoblastic leukemia who presented with bronchiolitis and died due 
to severe pneumonitis (Pelletier et al., 2002). Human metapneumovirus was 
also identified in nine percent of adults with haematological malignancies and 
respiratory tract infections tested, including three of whom died (Williams et 
al., 2005). In a prospective study conducted on high risk children in Argentina, 
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hMPV was found to be infrequent (12/567 episodes) but was a severe agent 
of lung disease (Klein et al., 2006). 
 
The burden of disease of respiratory viruses in South Africa has been shown 
to be increased in HIV infected children who have a poorer outcome and more 
severe disease (Madhi et al., 2000), however, there is no information on the 
impact of HIV on hMPV.  
 
1.5.1 Seasonality and circulation of the hMPV 
Data collected in recent reviews show that the hMPV season overlap with 
RSV and similar to influenza virus A/B and RSV causes seasonal epidemics 
(Hamelin et al., 2004; Hamelin and Boivin, 2005; Principi et al., 2006; van den 
Hoogen et al., 2004b) In temperate regions most of the viral activity was 
reported during the winter-spring month (Hamelin et al., 2004; Hamelin and 
Boivin, 2005; Principi et al., 2006; van den Hoogen et al., 2004b). In most of 
these studies, surveillance for hMPV has been limited to the respiratory 
season which was confirmed in a recent study conducted over a three period 
(October 2000-June 2003), showing higher hMPV activity in late winter-spring 
months (Garcia-Garcia et al., 2006). In contrast, viral activity was reported 
during the late spring-summer months in the subtropics (Peiris et al., 2003). 
 
The ability of hMPV to cause annual epidemics may be due to its genetic 
variation in the G protein and the existence of two major genetic groups and 
minor subgroups. 
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Table 1.1 The Prevalence of human metapneumovirus 
 
Study period1  Country  Prevalence (%)2  Study population/Comments  Type of study  References 
 
 
2000 (winter)  Netherlands 7/68 (10)  Children with ARTI   Retrospective  (van den Hoogen  2001) 
 
2000-2001 (winter) Canada  20/862 (2.3)  hMPV recovered from culture  Retrospective  (Boivin et al., 2002) 
        2 bacterial coinfections 
 
2001   Australia  23/00 (1.5)  Children with ARTI   Retrospective  (Nissen et al., 2002) 
 
09/00-05/01  Finland  10/132 (8)  Hospitalized children   Prospective  (Jartti et al., 2002) 
        with acute wheezing 
 
10/00-03/01  UK  9/405 (2.2)  All ages with ILI    Prospective  (Stockton et al., 2002) 
        Samples negative for other viruses. 
        HMPV detected in ages <1->65y 
        Community surveillance 
 
11/01-02/02  France  19/337 (6.6)  Hospitalized children with  ARTI  Retrospective  (Freymouth et al., 2003) 
        Negative for other respiratory viruses     
 
12/01-05/02  Canada  12/208 (5.8)  Hospitalized children <3y with ARTI  Prospective   (Boivin et al., 2003)
        0/51 control hMPV positive   Case control 
        2/12 co-infected with other viruses 
        Real time PCR 
 
10/01-02/02  USA  19/296 (6.4)  Children <5y    Laboratory based  (Esper et al., 2003) 
        1 nosocomial infection 
        2/19 co-infected 
 
05/01-08/02  Hong Kong 32/587 (5.5)  Children ≤18y with ARTI   Prospective  (Peiris et al., 2003) 
        Samples collected 1 or 2 a week. 
        2/32 co infected 
        1 case of nosocomial transmission 
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Study period1  Country  Prevalence (%)2  Study population/Comments  Type of study  References 
 
 
01/02-05/02  Germany 11/63 (17.5)  Hospitalized children <2 y with ARTI Retrospective  (Viazov et al., 2003) 
        hMPV detection by nested RT-PCR 
        3 children co-infected 
 
01/00-05/02  Italy  23/90 (25)  Children with ARTI   Retrospective  (Maggi et al., 2003) 
        Incidence varies over 3 years 
        37% in 2000, 7% in 2001 and 
        43% in 2002 
        9/23 co-infected 
        hMPV also detected in 7 plasma samples 
 
10/01-04/02  Canada  66/445 (14.4)  All ages with ARTI   Laboratory based  (Bastien et al., 2003b) 
        Specimens collected from 4 
        laboratories 
 
09/00-02/02  Netherlands 48/685 (7.0)  Persons all ages with ARTI  Laboratory based  (van den Hoogen 2003) 
        Most of hMPV<2y 
        6/48 co-infected 
 
1999-2001  USA  984 (4.5)  Young and elderly adults   Prospective  (Falsey et al., 2003) 
winter season       9/217 asymptomatic were hMPV 
        infected 
 
04/02-05/02   Brazil  19/111 (17)  Children <3 years ALRTI   Laboratory based  (Cuevas et al., 2003) 
        Study period correspondence   cross sectional study 
        to rainy season 
        8 coinfected with RSV 
 
1976-2001  USA  49/248 (20)  Children LRTI    Retrospective  (Williams et al., 2004) 
        Negative for other viruses 
        Estimated that 12% of LRTI  
        due to hMPV 
        15% of URTI due to hMPV 
        3 episodes of recurrent infection 
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Study period1  Country  Prevalence (%)2  Study population/Comments  Type of study  References 
 
 
06/00-05/03  Japan  57/637 (8.9)  Hospitalized and outpatients  Laboratory based  (Ebihara et al., 2004b) 
        children with ARTI 
        Samples collected from 3 
        different geographical areas 
 
06/02-08/02  South Africa 8/137 (5.8)  Hospitalized children   Prospective  (IJpma et al., 2004)
        between ages 15d-13.9y 
        13 tested HIV positive 
        1/8 hMPV infected 
        was HIV positive 
 
08/00-09/01  USA  26/668 (3.9)  Hospitalized children <5y   Population based- (Mullins et al., 2004) 
        with ARI/ARI-related   prospective 
        from 2 US cities 
        Nose and throat swabs 
        and not NPA 
        8/26 >1 mo premature 
 
11/02-04/03  Norway  50/236 (21)  Hospitalized children ARTI   Prospective  (Dollner et al., 2004) 
        41/50 had LRTI 
        10/50 co-infected with 
        other viruses 
        17/50 had CRP 66mg/l 
        on admission (pneumonia) 
 
11/01-10/02  USA  54/668 (8.1)  Children 5 years    Retrospective  (Esper et al., 2004) 
        Specimens previously negative 
        for other viruses 
        3 children had 2 specimens test 
        positive 7-54 days apart 
 
1998-2002  Argentina 11/100 (11)  Children <5 years with ARTI  Retrospective  (Galiano et al., 2004) 
        Samples were negative for 
        Respiratory virus 
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Study period1  Country  Prevalence (%)2  Study population/Comments  Type of study  References 
 
 
10/00-4/01  Germany 2/620 (<1)  Hospitalized and outpatient  Prospective  (Konig et al., 2004) 
        children <3 years    multicenter 
        Negative for other viruses 
        Community acquired 
        hMPV infections 
 
10/00-08/02  USA  54/868 (6.2)  Children ≤18 years   Retrospective study (McAdam et al., 2004) 
 
12/02-05/03  USA  52/719 (7.2)  Patients 1d-20 years old   Evaluation study  (Kuypers et al., 2005) 
        Real time RT-PCR 
 
11/02-03/03  Italy  42/1505 (2.8)  Children <15 years   Prospective  (Bosis et al., 2005) 
        7/42 coinfected 
        
 
08/97-03/00  Korea  26/166 (15.7)  Children < 5years with LRTI  Retrospective  (Kim and Lee, 2005) 
        5/26 coinfected with other viruses 
 
10/00-06/03  Spain  69/494 (14)  Hospitalized children   Prospective  (Garcia-Garcia , 2006) 
        <2y with ARTI 
        18/69 co-infected 
        1 child bacteremia 
        by S pneumoniae 
 
03/02-06/04  USA  202/3740 (5.45)  Children     Retrospective  (Agapov et al., 2006) 
        Real time PCR 
 
01/02-11/03  Peru  12/420 (2.9)  All ages (1-<89y)    Retrospective  (Gray et al., 2006b) 
        ILI 
        6/12 grew in culture 
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Study period1  Country  Prevalence (%)2  Study population/Comments  Type of study  References 
 
 
1982-2001  USA  118/2384 (5)  Infants and children with URTI  Retrospective  (Williams et al., 2006) 
        prospectively followed 
        from average 2.4y old 
        Real time PCR 
        Reinfection with homologous 
        and heterologous strains 
 
11/03-10/04  France  50/589 (8.5)  Hospitalized children <5y   Prospective  (Foulongne et al., 2006) 
        with RTI 
        16/50 dual infections 
        with other viruses 
        15 co infected with RSV 
 
06/03-05/05  Argentina 12/567 (2)  Premature infants and   Prospective  (Klein et al., 2006) 
        children with CHD and CLD 
 
11/01-10/02  Israel  68/517 (13)  Hospitalized children <5y   Prospective  (Wolf et al., 2006) 
        with LRTI 
        209/517 community acquired 
        pneumonia 
        16/68 co infected with other viruses 
 
12/03-05/04  Italy  40/306 (13.1)  Infants and young children   Prospective  (Sarasini et al., 2006) 
        10/40 coinfected with other viruses 
 
06/04-05/05  Japan  29/144 (20)  Children <17 y with RTI   Prospective  (Kaida et al., 2006) 
        103/141 children <3y 
        Nested RT-PCR 
 
10/01-05/04  USA  24/1294 (2.60  All ages     Retrospective  (Gray et al., 2006a) 
        21/24 grew in culture 
 
Footnote. 1 Study period refers to the month/year, eg.05/00 refers to May 2000. 2. The prevalence is based on the positive hMPV detected/ by either the total number of 
episodes or number of individuals and the value in parenthesis is the percentage. 
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Although all subgroups have been observed circulation in single communities 
in a single epidemic (Boivin et al., 2002; Esper et al., 2004; Gerna et al., 2005; 
Mackay et al., 2006; Mackay et al., 2004; Peret et al., 2004; Sarasini et al., 
2006; Williams et al., 2006) a single subgroup has been shown to 
predominate (Mackay et al., 2004; Peret et al., 2004). In Canada, subgroup 
B2 viruses predominated during the 1998 epidemic and in 2001 –2002 
epidemics subgroup A1 predominated (Peret et al., 2004). In Australia the co-
circulation of all four subgroups over 4 consecutive years (2001-2004) was 
observed with one subgroup predominating in each year (2001 subgroup A1; 
2002 subgroup A2; 2003 subgroup A2 and B1 and 2004 subgroup B1) 
(Mackay et al., 2006). Recently a study conducted over a 20 year period in the 
USA by Williams and co-workers report that all four subgroups have circulated 
in the community over 20 years with a single lineage dominating (Williams et 
al., 2006). Similarly a switch in predominant genotype from group A in 2003 to 
group B in 2004 was reported in another USA study (Agapov et al., 2006) This 
evidence suggests that like RSV (Sullender, 2000) strains from both groups of 
the hMPV can co-circulate in a single epidemic with a switch in predominant 
strain providing evidence that suggests that the hMPV may evade pre-existing 
community immunity through a switch in viral genotype  
 
1.5.2 Dual infection of human metapneumovirus with other respiratory 
pathogens 
Because of overlapping seasons of respiratory viruses, co-infection with 
multiple viruses may be common (Hamelin et al., 2004; Hamelin and Boivin, 
2005; Principi et al., 2006; van den Hoogen et al., 2004b).  
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Similarly hMPV has been identified in the presence of other respiratory 
viruses (Table 1.1). There is however conflicting data regarding the clinical 
significance of dual viral infection involving hMPV compared to illness that 
involves hMPV alone (Bosis et al., 2005; Maggi et al., 2003; Williams et al., 
2004; Xepapadaki et al., 2004).  
 
In the United Kingdom 70% of children with RSV bronchiolitis who required 
admission to the intensive care unit were co-infected with hMPV (Greensill et 
al., 2003). This increased severity due to co-infection between RSV and 
hMPV was replicated by Semple et al. who found that co-infected children 
required admission to ICU for mechanical ventilation (Semple et al., 2005). 
This increased severity was not observed in two other studies which did not 
detect hMPV in severe RSV-LRTI (Lazar et al., 2004; van Woensel et al., 
2006). 
 
In a prospective study involving children younger than three years of age, co-
infection with RSV and hMPV was associated with more severe disease, 
including 60% of co-infected infants requiring ICU admission (Konig et al., 
2004). Additionally, co-infection of hMPV with coronavirus in individuals with 
severe acute respiratory syndrome (SARS) was reported in Hong Kong and 
Canada (Chan et al., 2003; Chan et al., 2004; Poutanen et al., 2003).  
Studies in macaques with the SARS-associated coronavirus did not however 
result in more severe disease following subsequent infection by hMPV 
(Fouchier et al., 2003). In contrast, other studies did not find an increase in 
hMPV associated disease severity being linked with other concurrent viral 
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infections (Bosis et al., 2005; Maggi et al., 2003; Williams et al., 2004; 
Xepapadaki et al., 2004) and recently a co-infection rate of 26% was also not 
associated with more severe disease (Garcia-Garcia et al., 2006). 
 
1.5.3.Bacterial coinfections in viral- associated pneumonia 
Epidemiological studies as well as in vitro and animal studies have reported 
that viral infections predispose to bacterial disease probably by bacterial 
adherence induced by viruses (Beadling and Slifka, 2004; Hament et al., 
1999; Peltola and McCullers, 2004).  
 
Mechanisms through which superinfection might occur are poorly understood 
but may include physical damage to respiratory tract epithelium by viruses, 
virus induced immunosupression as well as the up regulation of bacterial host 
cell receptors through inflammatory response to viral infections  (Beadling and 
Slifka, 2004; Hament et al., 1999; Peltola and McCullers, 2004). Recently, 
Navarini et al used a mouse model to examine the enhanced susceptibility to 
bacterial superinfection. They showed that the production of IFN I due to viral 
infection caused apoptosis of granulocytes, resulting in the inability to control 
bacterial superinfection (Navarini et al., 2006). 
 
Pneumonia is a major cause of childhood morbidity and mortality, causing 
over 2 million deaths annually worldwide (Obaro and Madhi, 2006). Bacterial 
and viral vaccines are effective in limiting disease severity (Beadling and 
Slifka, 2004). A major obstacle to understanding the efficacy of vaccines 
against pneumonia and defining the role of bacterial coinfection is the lack of 
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sensitive tools to diagnose bacterial pneumonia. The WHO recommended 
tachypnoea with chest –wall indrawing as a clinical screening tool for the 
management of lower respiratory tract infections (WHO, 1990), however, 
laboratory confirmation of the bacterial etiology of pneumonia is limited. 
Although blood cultures may be specific, they lack sensitivity (10-15%) for 
confirming the bacterial etiology of pneumonia. The usefulness of chest 
radiographs in pneumonia is also controversial. Recently Madhi (2006) 
reported that in South Africa the sensitivity of chest radiograph-confirmed 
alveolar consolidation (CXR-AC) underestimated the burden of pneumococcal 
pneumonia prevented by pneumococcal conjugate vaccine (PCV) by up to 
63% (Madhi, 2006).  
 
Although controversial, biochemical markers such as C-reactive protein (CRP) 
and procalcitonin have been shown to be useful for diagnosis of 
pneumococcal pneumonia (Madhi et al., 2005a; Simon et al., 2004). 
Examining the efficacy of a nine-valent pneumococcal conjugate vaccine, 
Madhi et al. showed that the efficacy of 9-PCV associated with CXR-AR 
among HIV uninfected children compared to controls was 21% (P=0.04) and 
increased to 38% (P=0.05) when associated with CXR-AR and CRP (level ≥ 
120mg/l).  
 
The efficacy of the vaccine increased considerably to 64% (P=0.006) when 
procalcitonin (level 5.0ng/ml) was added to CXR-AR and CRP. More recently, 
it has been also been shown that a CRP level of ≥ 40mg/l may provide a 
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better assessment of the effect of PCV in preventing pneumonia compared to 
chest radiographs and procalcitonin (Madhi et al., 2006).  
 
The use of vaccine as a probe to define the burden of disease may be a 
powerful tool due the lack of sensitive laboratory diagnostic tools (Obaro and 
Madhi, 2006). This method also has its shortcoming and may also 
underestimate the burden of disease as the proportion of disease preventable 
by the vaccine will only be equal to disease burden when the vaccine is 100 % 
effective (Obaro and Madhi, 2006). Using the 9-valent PCV to examine the 
role of Streptocococcus pneumoniae in the etiology of viral pneumonia, Madhi 
and Klugman showed a 31% overall reduction in the incidence of 
hospitalization for viral associated pneumonias in all children (HIV infected 
and HIV uninfected) among the vaccinees (Madhi and Klugman, 2004). This 
suggested that receipt of PCV-9 reduced the risk of superimposed 
pneumococcal infection from occurring among PCV-9 vaccinees in children 
that may have been infected with the respiratory viruses in the community. 
Overall there was a 45% (p=0.01) reduction in Influenza A, 22% (p=0.08) 
reduction in RSV and 44% (p=0.02) reduction in PIV types 1-3 associated 
pneumonia in (Madhi and Klugman, 2004).  
 
There is little evidence of the importance of bacterial co-infections in children 
with hMPV-associated LRTI. Boivin et al. reported on two cases in whom 
Streptococcus pneumoniae and Staphylococcus aureus was present in 
respiratory secretions from 12 samples concurrent with hMPV infection (Boivin 
et al., 2002). Dollner et al. reported that children with hMPV-associated 
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pneumonia had high CRP levels (median, 105.5mg/l [ranged <5-281 mg/l]) 
most likely reflecting undiagnosed bacterial coinfection in those children. 
Further in that study children with hMPV-associated LRTI had high 
temperatures (mean, 39.9oC) (Dollner et al., 2004), a known predictor of 
bacterial infection (Banya et al., 1996).  
 
1.5.4 Antigenic characteristics  
The observed genetic variability may lead to antigenic variability and the two 
hMPV genetic clusters may represent two distinct antigenic groups. There is 
conflicting evidence as to whether the two genetic clusters are in fact two 
antigenic groups.  
 
Using antisera raised in ferrets against the two genetic groups for virus 
neutralizing assays, van den Hoogen and coworkers showed that the two 
genetic groups (A and B) were antigenically different based on the definition 
that a homologous to heterologous neutralization titer of >16 defines a 
serotype (van den Hoogen et al., 2004a). The antigenic diversity was also 
addressed by Bastein et al. using western blot analysis and 
immunoprecipitation of the G protein with polyclonal antibodies raised against 
strains specific to each group isolated in Canada (Bastien et al., 2004).  
This study showed that the detection of the G protein was group specific and 
also demonstrated that the G protein is N and O linked glycosylated (Bastien 
et al., 2004). MacPhail et al. studying the replication of hMPV in different 
animals reported that in Syrian golden hamsters there was cross protection 
between hMPV subgroups A or B, suggesting that there was no antigenic 
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difference between the groups and a vaccine based on either group may be 
effective (MacPhail et al., 2004). A study designed to address the antigenic 
relatedness of the two groups found them to be highly related antigenically 
(48% in hamsters and 64%-99% in non-human primates) demonstrating a 
high level of cross protection (Skiadopoulos et al., 2004). This study also 
showed that the hMPV F gene is the major neutralization antigen and 
conferring substantial neutralization and protection across lineages, a finding 
that was subsequently confirmed (Skiadopoulos et al., 2006), and also 
showed that the G protein was not a major neutralizing or protective antigen. 
The antigenic relatedness of the two groups needs to be addressed further as 
this conflicting evidence may have implications for the development of an 
effective vaccine. 
 
1.5.5 Reinfection with hMPV  
Serological data has shown that the hMPV antibody titer was higher in older 
individuals (>2 years) compared to younger individuals (Ebihara et al., 2003), 
suggesting a booster effect probably due to re-infection. Re-infection with the 
hMPV was reported in a 7 month old immunocompromised child who had 
severe LRTI and was infected with two genetically distinct hMPV strains 
(Pelletier et al., 2002).  
 
The symptoms of the first episode was a cold that progressed to bronchiolitis, 
the second episode which occurred about 10 months later also started with a 
common cold but deteriorated to bilateral pneumonitis and death (Pelletier et 
al., 2002). Another study reported a 9 month old girl re-infected with a 
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heterologous strain of hMPV in a space of 19 days (Ebihara et al., 2004a). 
Subgroup A1 hMPV was identified as the cause of the initial illness and the 
second illness was caused by a subgroup B2 virus. The re-infection with 
subgroup B2 strain was associated with a more severe illness, resulting in the 
onset of wheezy bronchitis and pneumonia (Ebihara et al., 2004a). Studies by 
William et al reported that among children with hMPV-LRTI associated illness 
a recurrent infection was associated with upper respiratory tract (URT) several 
months/years of age later. This indicated primary immunity induced by 
infection of the LRTI (lower respiratory tract infection) reduced the severity of 
subsequent infections and limited the replication of hMPV to the URT 
(Williams et al., 2004; Williams et al., 2006).  
 
1.5.6 Virulence difference 
It is possible that there may be an association between disease severity and 
hMPV subgroup; however, this remains to be addressed fully. It has been 
suggested that subgroup A2 may be linked to more severe disease as it has 
been detected more often than other subgroups (Mackay et al., 2004) 
Recently a study designed to examine the difference found that group A 
viruses were more virulent than group B and the difference in severity was not 
due to underlying medical conditions (Vicente et al., 2006).  
 
In contrast a study in Japan did not find any significant difference for rates of 
hospitalization between the groups to suggest a difference in severity (Ebihara 
et al., 2004b) and a study from St Louis, USA found similar rates of illness for 
either group (Agapov et al., 2006). Such conflicting evidence has also been 
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reported for RSV (Sullender, 2000) and it has been suggested that difference 
may be due to the inclusion of only hospitalized patients that were severely ill 
(Cane, 2001) or that host genetic factors may influence the susceptibility 
(Stark et al., 2002). Alternatively if studies are not done over an extended time 
period, the introduction of a new subgroup of virus into the community may be 
temporally related to more severe disease being observed for that subgroup 
of virus.  
 
1.5. Objectives 
The objectives of this study were:  
i. to investigate the molecular epidemiology of hMPV in South Africa;  
ii. characterize the burden of severe hMPV associated LRTI; and determine 
the clinical features of hMPV-LRTI in children infected and not infected by 
HIV;  
iii. probe the role of Streptococcus pneumoniae in the pathogenesis of hMPV-
LRTI.  
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CHAPTER 2 
STUDY MATERIALS AND METHODS 
2.1. Study population 
The nasopharyngeal aspirates (NPAs) used in this study were collected from 
children participating in a phase 3 study of which the primary objective was to 
determine the efficacy of a PCV-9 in preventing invasive pneumocococcal 
disease and radiographically confirmed pneumonia in South Africa. Details of 
the study have been previously published (Klugman et al., 2003; Madhi and 
Klugman, 2004). Briefly stated, recruitment of 39836 children was started on 
the 1 March 1998 and enrolment of all the subjects was completed by October 
2000, with the last child being immunized in December 2000. The first dose of 
study vaccine was administered at a mean age of 6.6 (standard deviation 
[S.D.] 1.2) weeks and a further two doses of study-vaccine were administered 
at 11.2 (S.D. 2.5) and 15.9 (S.D.3.8) weeks respectively, with no booster dose 
of PCV given. Surveillance for study-outcome cases was hospital-based and 
continued until 15th November 2001, at which stage the data were analyzed 
for the primary objectives of the study. Thereafter, investigators and laboratory 
staff remained blinded to the randomization arm of the individual subjects and 
surveillance continued until October 2005. All children that were hospitalized 
were clinically evaluated by one of the study-doctors who used a standardized 
form for documenting signs and symptoms. The decision to hospitalize 
children was done as part of routine patient management by the attending 
physicians and independent of the study.  
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Children would either have been referred from a primary health-care clinic or 
self-referred directly to the hospital by the parent. There is no known 
difference in clinical criteria for hospitalization of HIV infected and HIV 
uninfected children. The present study is limited to surveillance that occurred 
from 1st January 2000 until 31st December 2002 as prior to this period 
samples were not routinely archived. 
 
2.2 Collection of nasopharyngeal aspirates 
Nasopharyngeal aspirates were collected within 24 hours of admission to 
hospital and surveillance was conducted by a study staff doctor at the Chris 
Hani-Baragwanath hospital. Nasal secretion samples were obtained using a 
nasogastric tube (FG 8 x 10 cm in length, Ven Medical Products, South 
Africa), attached to a 5 ml syringe containing 3ml of normal saline. The saline 
was injected into the nasopharynx and aspirated immediately. An aspirate of 
1-2 ml was obtained from the children. On arrival at the laboratory the 
samples were aliquoted and tested for other respiratory viruses. An aliquot 
was stored at –70oC was subsequently used for the testing of hMPV in this 
study. 
 
2.3 Respiratory virus identification 
The NPA samples were used to test for common respiratory viruses. The 
specimens were centrifuged and the pellet was spread onto a microscope 
slide and fixed. Initially screening was performed by a direct pooled 
immunofluorescent test for respiratory viruses.  
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Positive samples were tested for RSV by means of mouse anti-RSV 
monoclonal fluorescent antibody (Chemicon International Inc; Temecula, 
California, USA). Specimens that tested negative for RSV were subsequently 
examined for each of seven respiratory viruses (RSV, influenza A and B, PIV 
1,2,3 and adenovirus) using specific monoclonal fluorescein conjugated 
antibodies (Chemicon International; Temecula, California, USA).  
 
2.4. Identification of hMPV 
2.4.1 RNA extractions 
Viral RNA was extracted from the stored frozen nasopharyngeal aspirates 
using the QIAamp viral RNA kit (Qiagen). Viscous NPAs that were difficult to 
pipette were homogenized with QIAshredder homogenizer columns (Qiagen, 
Hilden, Germany) and the flow-through was used for viral RNA extraction. The 
extraction was performed according to the manufacturer’s instructions. A 
volume of the thawed NPA was treated for RNases and lysed with a buffer 
provided by the manufacturer. This was followed by the addition of ethanol for 
precipitation of the viral RNA. Following centrifugation the viral RNA becomes 
attached to a membrane with the help of the carrier RNA. The attached viral 
RNA was washed twice and eluted with RNase-free water provided by the 
manufacturer and stored at –20oC.  
 
2.4.2. RT-PCR and nested PCR: F gene 
A nested RT-PCR with primers designed for the fusion (F) gene was used for 
the identification of hMPV from NPAs. The F gene is highly conserved and a 
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nested RT-PCR assay was necessary to increase the sensitivity for detection 
and increase the yield of PCR product for sequencing. 
2.4.2.1 RT-PCR: F gene 
Single step RT-PCR assays have an advantage over a two step RT-PCR as it 
is fast and decreases the risk of contamination. To prevent the possibility of 
contamination, a single step RT-PCR assay was considered because of its 
advantages over a two-step assay. hMPV viral RNA was amplified using the 
SUPERSCRIPT One-Step RT-PCR kit (Invitrogen). The viral RNA was initially 
amplified by RT-PCR in a 50μl reaction mix as recommended by the 
manufacturer and was subsequently optimized for a 25μl reaction, 
considerably reducing the cost for each reaction. The primers used for the 
primary RT-PCR reaction span the F gene and correspond to nucleotide 
sequences position 3052-3069 (primer Fatg) and 3844-3862 (primer Frev) in 
the NL/1/00 genome (accession number AF371337) and are shown in Table 
2.1 were used for the diagnosis of hMPV. 
 
Each 25μl reaction contained 12.5μl of a 2X reaction mix that was provided by 
the manufacturer of the kit, 0.6μM of each primer (final concentration, 
Fatg/Frev Table 2.1), 3mM MgSO4 (final concentration), 0.4mM dNTPs 
(dTTP, dATP, dGTP, dCTP at final concentrations), 0.25μl of RT/Taq enzyme 
mix and 5μl of viral RNA all made up to 25μl with sterile water. 
 
The RT-PCR reaction was performed in an Eppendorf Mastercycler 
(Eppendorf) as follows: reverse transcription at 50oC for 30 min, an initial 
denaturation step at 94oC for 2 min, followed by 35 cycles at 94oC for 30 sec, 
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45oC for 45 sec and 68oC for 1min. No template controls (NTCs) and a 
negative control (specimens that were negative for hMPV) was included. 
2.4.2.2 Nested PCR: F gene 
To increase the sensitivity and the yield for sequencing, a second round of 
PCR was performed. Two microliters of the RT-PCR product was used as the 
starting template for the nested PCR. A 50μl reaction containing at final 
concentrations the following reagents: 1X reaction buffer, 3mM MgCl2, 400μM 
dNTP, 0.6μM each primer (Ffor/Fnest Table 2.1, corresponding to nucleotide 
positions 3130-3149 and 3794-3810, respectively in the NL/1/00 genome, 
accession number: AF371337) and 1.25U Taq made up to volume with sterile 
water, was prepared for each reaction.  
 
The cycling parameters were as follows: initial denaturation for 2 min at 94oC, 
followed by 30 cycles at 94oC, 48oC and 72oC for 1 min each and a final 
extension at 72oC for 7 min. 
 
2.4.3 RT-PCR:G protein gene 
The G gene was also analyzed using a nested RT-PCR approach. The 
primers for the detection of the G gene are shown in Table 2.1 and 
correspond to nucleotide position 6262-6285 (HMPVGunivF) and 7181-7204 
(HMPVGunivR) in the NL/1/00 genome accession number, AF371337, this 
primer amplified an 800-1000bp region of the hMPV G protein gene. 
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The viral RNA was reverse transcribed at 50oC for 30 min, followed by an 
initial denaturation at 95oC for 3 min, 38 cycles of PCR as follows: 94oC for 1 
min, 59oC for 1 min and 72oC for 2 min and a final extension at 72oC for 7 min. 
To increase the yield for sequencing a nested PCR was performed using the 
same primers set. 
 
2.5 Analysis of the PCR product 
The nested PCR products for both the F and G genes were visualized on a 
2% ethidium bromide stained agarose gel on a UV transilluminator and 
photographs of the gels were taken with a Kodak polariod camera. In addition 
to the positive control a molecular weight marker (DNA molecular marker VI, 
Roche diagnostics, Mannheim, Germany) was included to verify a positive 
result.  
 
2.6 Nucleotide sequencing 
The F and the G gene were sequenced in this study. The PCR products were 
purified using the QIAquick gel extraction kit (QIAGEN, GmbH) and 
sequenced in both directions. Cycle sequencing for the F gene was performed 
with the nested primers (Ffor and Frev) and for the G gene the primers used 
for detecting the G gene (HMPVGunivF and R) in Table 2.1. Sequencing of 
the PCR product was carried out using the BigDye Terminator Cycle 
sequencing kit v3.1 (Applied Biosystems, Foster City, Calif) on the ABI 310 
Genetic Analyzer (Applied Biosystems). The nucleotide sequences were 
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edited using Chromas version 1.43 software and saved as text files in FASTA 
format. 
 
2.6.1 Nucleotide sequence accession numbers 
The hMPV nucleotide sequences from this study have been deposited in 
Genbank under the following accession numbers AY694693 to AY694784 for 
the F gene and AY848859 to AY848919 for the G gene. 
 
2.7 Phylogenetic analysis and genetic identities 
Nucleotide sequences from F and G genes were aligned with CLUSTAL X 
1.64b (Thompson et al., 1997) using the multiple alignment option. 
Phylogenetic trees were constructed on the aligned nucleotide sequences 
with the neighbour-joining (NJ) method using the Nucleotide: Kumira 2-
parameters in MEGA version 2.1 (Kumar et al., 2001a). Statistical evaluations 
of the NJ trees were carried out by bootstrap evaluation (500 bootstrap 
replicates). 
 
Genetic identities for both nucleotide and amino acid were computed on the 
aligned sequences with Bioedit software. The identities were determined as 
the proportion of differences, i.e. the number of pair-wise nucleotide or amino 
acid differences divided by the total number of nucleotides or amino acids in 
the sequenced region. 
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The potential structure of the attachment protein (G protein) was predicted 
using the hydropathy plot of Kyte and Doolittle (Kyte and Doolittle, 1982) in 
the Bioedit software package. The hydrophobicity score for the amino acids 
were between -4.5 and 4.5. 
2.8 HIV testing 
The HIV infection status of individual subjects who were hospitalized was 
determined using two HIV ELISA test (Axsym® and Murex* HIV 1+2, Murex 
Diagnostic Limited, Dartford, England). A HIV PCR (Roche Amplicor version 
1.5, Nutley, NY) test was used to confirm the infections status of children <18 
month of age if the ELISA test was reactive or if any child had a non-reactive 
HIV ELISA test despite the presence of stigmata of acquired 
immunodeficiency virus syndrome (AIDS).  
 
2.9 C-reactive protein (CRP) 
C-reactive protein (CRP) tests were performed using immunoturbidometry 
(717 Automated Analyzer, Boehringer Mannheim/Hitachi, Mannheim, 
Germany) at the National Health Laboratory Service, South Africa.  
Samples were sent for testing either by the attending physician at the time of 
admission of the child to hospital or serum that was obtained within 12 hours 
of admission that was stored at -700C was retrospectively analyzed for CRP 
when available. 
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Table 2.1 Sequences of primers used for the detection and sequencing of human metapneumovirus 
Primers Gene NL/1/00 corresponding nucleotide positions Sequence (5’-3’) 
Fatg Fusion protein (F gene) 3052-3069 
 
ATGTCTTGGAAAGTGGTG 
Frev Fusion protein (F gene) 3844-3862 
 
CCATGTAAATTACGGAGC 
Ffor Fusion protein (F gene) 3130-3149 
 
TCATGTAGCACTATAACT 
Fnest Fusion protein (F gene) 3794-3810 
 
TCTTCTTACCATTGCAC 
HMPVGunivF Attachment protein (G gene) 6262-6285 
 
GAGAACATTCGRRCRATAYATG 
HMPVGunivR Attachment protein (G gene) 7181-7204 
 
AGATAGACATTRACAGTGGATTCA 
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Figure 2.1 A 2% ethidium bromide stained agarose gel showing the nested 
PCR product as amplified using primers spanning the F gene. Lanes 1-9 are 
different patient samples that are positives for hMPV. Lane 10 is a positive 
control sample provided by Dr Guy Boivin, lane 11 is a NTC and lane 12 is a 
100 bp molecular weight marker.  
 
 1       2        3       4        5       6       7      8      9      10       11     12  
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2.10 Statistical Analysis 
Statistical analysis was performed using Epi Info version 6.04c (Atlanta, 
Georgia, USA), SAS (SAS Institute, Cary, North Carolina, USA) and STAT 
version 8.0 (StataCorp LP, College Station, TX, USA). Continuous and 
categorical variables were analyzed using unpaired Student t-test and Mantel-
Haenszel chi-square test, respectively. Fisher’s exact test was used when a 
cell had an expected value of fewer than five observations. Median (25th-75th 
centiles) were used for all age-related analyses and the mean and standard 
deviation (S.D) were calculated for continuous variables. Relative risks (R.R) 
and 95% confidence intervals (CI95%) were used in describing risk differences 
between HIV infected and HIV uninfected children. 
 
As receipt of PCV may have impacted on the epidemiology of hMPV 
associated hospitalization as has been described for other respiratory viruses 
(Madhi and Klugman, 2004), the calculation of the incidence rate of 
hospitalization for hMPV-LRTI was limited to placebo recipients. 
 
2.10.1 Vaccine Efficacy (VE) 
Vaccine efficacy was calculated using the vaccine efficacy calculation in Epi 
Info version 6.04d for cohort studies. This is based on the formula: V.E. (%) = 
(incidence rate in the unvaccinated – incidence rate in the vaccinated)/ 
incidence rate in unvaccinated} x 100. All children that were randomized were 
included in the intent-to-treat (ITT) analysis from the day of receiving their first 
dose of study vaccine.  
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Children were considered to be fully vaccinated and included in the per 
protocol (PP) analysis if the event occurred more than 14 days following the 
third dose of study vaccine and the child received all the study- vaccines as 
per planned schedule.  
 
Only the first episode of any clinical syndrome was included in the respective 
“vaccine efficacy” calculation. Trends in hMPV-LRTI between vaccinees and 
placebo recipients among children <6.0 months, 6.1-12.0 months, 12.1-24 
months and >24.0 months of age at the time of hospitalization were calculated 
using Mantel-Haenszel chi-square. An alpha of ≤ 0.05 was considered as 
significant. 
 
2.11 Definitions  
The clinical definitions of the spectrum of LRTI listed below have been 
previously defined by Madhi et al. and have been adopted for this study as 
well (Madhi, 2003). 
 
2.11.1 Severe lower respiratory tract infection (LRTI) 
The diagnosis of LRTI was based on WHO clinical criteria, which was 
complemented by pulse oximetry. Children were enrolled if they had a history 
of cough of less than two weeks duration and fulfilled at least one of the 
following criteria: 1) tachypnea – defined as a respiratory rate >50/breath/min 
between 2-12 months of age and 40 breaths/min in older children; and the 
presence of lower chest wall in drawing (and/or intercostals recession in 
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malnourished children); 2) An arterial oxygen saturation of <90% room air, as 
measured by pulse oximetry. 
 
2.11.2 Respiratory viral associated LRTI 
Children with LRTI in whom respiratory virus antigen was detected by 
immunofluorescence from NPAs were categorized as having viral associated 
LRTI. 
 
2.11.3 Bronchiolitis 
A clinical diagnosis of bronchiolitis was made if the child was less than two 
years of age and had bilateral diffuse wheezing with or without the presence 
of bilateral crackles, or in the presence of clinical and/or radiographic signs of 
hyperinflation the absence of any adventitious sounds and other evidence of 
airspace infiltration on chest radiograph. 
 
2.11.4 Pneumonia 
Children who have evidence of crackles in the absence of wheezing, or no 
adventitious sounds on chest auscultation in the presence of any airspace 
consolidation on chest radiograph, or alveolar consolidation on chest 
radiograph were categorized as having pneumonia. 
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CHAPTER 3 
PREVALENCE AND BURDEN OF DISEASES OF THE 
HMPV IN HIV UNINFECTED AND HIV INFECTED 
CHILDREN HOSPITALIZED WITH LRTI OVER A 3 
YEAR PERIOD IN SOUTH AFRICA 
3.1 Study sample 
Figure 3.1 gives a summary of the children that were hospitalized with LRTI 
(bronchiolitis and pneumonia) during the study period January 2000 to 
December 2002. During this period there were 3176 episodes of LRTI 
requiring hospitalization of which NPA were performed on 3069 (96.6%) 
samples. Of the 3069 episodes, 2715 (88.5%) samples were available for 
hMPV testing. The HIV status was available for only 2678 (98.6%). There was 
no significant difference (P > 0.99) between the samples for which NPA were 
done and the samples that were available for hMPV testing, both overall and 
between HIV infected and HIV uninfected.  
 
Children in whom NPA samples were unavailable for further hMPV testing 
(354 [11.5%] of 3069) were younger median [range] age-months: 9.3 [1.4-
54.7] vs 13.8 [1.2-56.1], P <0.001) and were 1.9 fold (95% C.I 1.5-2.5) more 
likely to have one of the other respiratory viruses identified (133 [37.65] of 354 
vs 645 [23.8%] of 2715; P<0.0001) than in whom NPA were available for 
hMPV testing. These differences were evident in HIV infected as well as in 
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HIV uninfected children. There was however no clinical or demographic 
differences regarding LRTI episodes for which NPA were unavailable. 
 
3.2 hMPV in hospitalized children  
Overall a total of 3302 NPA samples were tested for hMPV in children with 
respiratory illness of which 2715 samples were from children with LRTI. This 
study is limited to children with LRTI as the samples from children with other 
respiratory illness were not done in a systematic manner. 
 
Human metapneumovirus was identified from 230 NPA samples tested in 
children with a respiratory tract illness. A clinical diagnosis of LRTI was made 
in 202 (87.8%) of the 230 hospitalizations associated with hMPV and the 
remaining 28 (12.2%) episodes were associated with respiratory symptoms in 
children with a non-LRTI illness. Except for a single HIV infected vaccine 
recipient with lymphocytic interstitial pneumonitis, the remaining 27 non-LRTI 
cases of hMPV-associated hospitalization occurred in HIV uninfected children. 
The spectrum of illness’ (including multiple diagnosis) observed in these HIV 
uninfected children included: nine children with acute exacerbation of hyper-
reactive airway disease/asthma, eight episodes of upper respiratory tract 
infection, eight episodes of febrile convulsions, two episodes each of break-
through epileptic seizures or gastroenteritis and one case each of 
pneumococcal septicemia and tuberculosis meningitis.  
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Figure 3.1: Summary of children hospitalized for lower respiratory tract infection that were investigated for human metapneumovirus 
infection in South Africa1LRTI episodes= total number of lower respiratory tract infections (bronchiolitis or pneumonia). 2NPA done= 
nasopharyngeal aspirate performed to test for respiratory viruses other than hMPV. 3RT-PCR done= Number of NPA samples that 
were available for reverse-transcriptase polymerase chain reaction (RT-PCR) assay to detect hMPV.  
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3.3 Prevalence of hMPV in episodes of LRTI  
Among the 2715 episodes of LRTI, 202 (7.4%) samples were positive for 
hMPV (Figure 3.1). hMPV was identified in 154 (9.1%) of 1686 samples in HIV 
uninfected children compared to 45 (4.5%) of the 992 samples in HIV infected 
children (P=0.001). Overall hMPV was identified in 76 children that were given 
the PCV and 126 that were given placebo (P=0.01). Of the 76 PCV recipients 
positive for the hMPV, 60 (78.9%) were HIV uninfected and 16 (21.1%) were 
HIV infected compared to placebo recipients where 94 (76.4%) were HIV 
uninfected and 29 (23.6%) were HIV infected. The HIV infection status was 
unknown for three of the children with hMPV that had received placebo. 
 
3.4 Burden of hMPV-LRTI hospitalization in HIV-infected and –
uninfected children not vaccinated with PCV 
The data from children that were given the placebo were used to investigate 
the burden of hMPV. Samples were available for hMPV testing in 2715 
(85.5%) of the 3176 episodes of LRTI hospitalizations. Among the placebo 
recipients that were available for hMPV testing, 1409 (85.8%) of the 1643 
episodes of LRTI required hospitalization. There was no difference in the 
proportion of LRTI episodes for which samples were available for hMPV 
testing between HIV uninfected children (851 [87.5%]) of 973) and HIV 
infected children (536 [84.4%] of 635, P=0.08). Human metapneumovirus was 
identified in a lower proportion of HIV infected children (29 [5.4%] of 536) than 
HIV uninfected children (94 [11.1%] of 973, P=0.004; Table 3.1).  
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Table 3.1: Prevalence of identifying human metapneumovirus (hMPV) compared to other studied respiratory viruses in children not 
vaccinated with a pneumococcal conjugate vaccine. 
Virus identified                      Overall1     HIV uninfected children2  HIV infected children3 
 N  (%)4 O.R. (95% C.I.)5 N (%)4 O.R. (95%C.I.)5 N (%)4 O.R. (95%C.I.); P=5 
RSV6 240 (15.1) 0.55 (0.44-0.70)8  201 (21.1) 0.46 (0.35-0.61)8 31 (5.1) 1.07 (0.62-1.86); P=0.79 
Influenza A virus   73 ( 4.6) 2.04 (1.50-2.78)8  46 ( 4.8) 2.44 (1.67-3.58)8 22 (3.6) 1.59 (0.87-2.91); P=0.10 
PIV 1-37   52 ( 3.3) 2.56 (1.82-3.62)8  33 ( 3.5) 3.45 (2.26-5.31)8 18 (2.9) 1.89 (1.0-3.59); P=0.04 
Adenovirus   32 ( 2.0) 4.79 (3.18-7.26)8  27 ( 2.8) 4.25 (2.69-6.75)8   5 (0.8) 6.96 (2.54-20.6); P<0.0001
HMPV 126  (8.9)    Not applicable  94 (11.1) Not applicable 29 (5.4) Not applicable 
  1Total 1 643 LRTI episodes of which 1 593 tested for viruses other than hMPV and 1409 samples available for hMPV testing.  2 Total 973 LRTI episodes of 
which 951 tested for viruses other than hMPV and 851 samples available for hMPV testing.  3 Total 635 episodes of LRTI of which 613 episodes tested for 
viruses other than hMPV and 536 samples available for hMPV testing. 4Number in column refers to number of isolates and value in parenthesis is a 
percentage of the number of samples tested for that virus. 5Refers to comparing prevalence of identifying the specified virus relative to that of identifying 
hMPV. [Odds ratio (O.R.) 95% confidence interval (95%C.I.); P value (P=)]. 6RSV: respiratory syncytial virus. 7 PIV: parainfluenza virus type 1-3. 8P value 
<0.0001 
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The overall incidence of hMPV-LRTI was however 5.0 (95%C.I.3.3-7.5) fold 
greater in HIV infected children (incidence rate: 2 504 [95%C.I. 1 683-3 577] 
per 100 000) than in HIV uninfected children (incidence rate: 505 [95%C.I. 
409-618] per 100 000, P<0.0001). The estimated incidence of hMPV-LRTI in 
these children, after adjusting for those episodes of LRTI for which specimens 
were unavailable for hMPV testing, was 2 936 [95%C.I.2 042-4 079] per100 
000 in HIV infected children and 575 [95%C.I. 472-695] per 100 000 in HIV 
uninfected children, R.R.5.4; 95%C.I. 3.5-7.5, P<0.0001. 
 
3.5 Seasonality off hMPV in relation to other studied 
respiratory viruses 
Figure 3.2 shows the seasonality of hMPV in relation to the other viruses, 
including all episodes of LRTI that were investigated for the other viruses. 
Human metapneumovirus was identified throughout each of the three years; 
however identification of hMPV peaked during the autumn-winter months 
(April-August). The season appears to follow the RSV season and precede 
the influenza and parainfluenza seasons.  
 
3.6 Prevalence of hMPV in relation to other studied respiratory 
viruses 
Among all the children not vaccinated with PCV, hMPV was identified (126 
[8.9%] of 1 409, Figure 3.1) less frequently than RSV (15.1%; P<0.0001), but 
more commonly than influenza A/B virus (4.6%; P<0.0001), PIV 1-3 virus 
(3.3%; P<0.0001) and adenovirus (2.0%; P<0.0001; Table 3.1).  
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Similarly, identification of hMPV (11.1%) was less common than RSV (21.1%; 
P<0.000) but more frequent than any of the other studied viruses (P<0.0001, 
Table 3.1) in HIV uninfected children. Among HIV infected children hMPV 
(5.4%; Table 3.1) was identified more commonly than parainfluenza type 1-3 
(2.9%; P=0.04) and adenovirus (0.8%; P=0.001). These comparisons did not 
differ significantly when restricting the analyses to only those episodes of LRTI 
for which samples were available for hMPV testing (data not shown) 
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Figure 3.2: Seasonal variation in identifying different respiratory viruses in 
children hospitalized for lower respiratory tract infection between January 
2000 until December 2002. 
Legend: ——■——:respiratory syncytial virus (RSV); - - -▲- - - :influenza A 
virus; - - -♦ - - -: human metapneumovirus (hMPV);    ——□——:parainfluenza 
virus type 1-3.  
Note: Includes all the respiratory viruses that were identified during this study 
period in the cohort of children participating in the phase 3 pneumococcal 
conjugate vaccine efficacy study. Samples were only available on a subgroup 
of children (N=2 715 [88.5%] of 3 069 children on whom nasopharyngeal 
swabs were performed) for human metapneumovirus testing. 
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3.7 Clinical features of human metapneumovirus associated 
lower respiratory tract infections  
Among children in whom hMPV was identified, the only statistically significant 
difference in the clinical features listed in Table 3.2 between PCV and placebo 
recipients was that HIV infected PCV recipients were less likely  (2 [12.5%] of 
16 vs. 13 [44.8%] of 29, P=0.05) to have alveolar consolidation on chest 
radiographs. The data from PCV and placebo recipients were therefore 
combined when analyzing the demographic and clinical features of children 
with hMPV-LRTI (Table 3.2). The overall mean age of children with hMPV-
LRTI was 13.3 months and HIV infected children with hMPV-LRTI were older 
(mean 17.6 months) than HIV uninfected children (12.3 months; P=0.007). 
Furthermore, HIV infected children had a longer duration of hospital stay (5.8 
vs. 4.1 days, P=0.003) as well as a higher mortality rate (4.4 vs. 0%, P=0.05) 
compared to HIV uninfected children (Table 3.2). Both of the children who 
died were HIV infected and were males aged 4.5 and 21.7 months. The 
younger of these children had concurrent Pneumocystis jiroveci pneumonia 
(PCP). The older HIV infected child who died was not investigated for PCP. 
The only child that required mechanical ventilatory support was a 4 month old 
HIV uninfected child from whom RSV was concurrently identified from the 
nasal aspirate.  
 
Additional differences observed between HIV infected children and HIV-
uninfected children are shown in Table 3.2. These included the observations 
that HIV infected children were more likely to have concurrent bacteremia 
(16.3% vs. 0%, P<0.0001), had higher median CRP levels (43mg/l; P=0.04) 
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nd were more likely to present with pneumonia than bronchiolitis (P=0.0001). 
Pneumocystis jiroveci pneumonia was diagnosed in two (25%) of eight HIV 
infected children with hMPV-LRTI in whom an immunofluorescence assay 
was performed to identify Pneumocystis jiroveci cysts. Concurrent respiratory 
viral infections occurred in one HIV infected child and 12 (7.8%) of 154 HIV 
uninfected children. This mainly involved the co-presence of respiratory 
syncytial virus (8 [61.5%] of 13], Table 3.2. 
 
3.8 Discussion 
Serological diagnostic testing requires paired sera (acute and convalescent 
sample) and hMPV replicates slowly in culture and may also yield false 
positives (Ebihara et al., 2004b) making both of these methods unsuitable for 
clinically investigating for hMPV-associated disease. RT-PCR is sensitive, 
less labour intensive and does not require sophisticated equipment. It has 
been used by most studies that have investigated the prevalence of hMPV 
(Hamelin et al., 2004; Hamelin and Boivin, 2005). The present study used a 
nested RT-PCR assay to detect for hMPV RNA isolated from stored 
nasopharyngeal aspirates. The primary RT-PCR was done using a one step 
approach to avoid contamination that may have arisen due to the high 
throughput (2715 samples) of samples. The nested PCR was used to 
increase the sensitivity of PCR as the yield of RNA from stored NPA may be 
suboptimal. 
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Table 3.2: Demographic and clinical characteristics of human immunodeficiency virus type-1 (HIV) infected and -uninfected children 
hospitalized for human metapneumovirus (hMPV) associated lower respiratory tract infections 
Demographic/ clinical feature Overall                          
N=202 
HIV infected              
N=45 
HIV uninfected          
N=154 
P value1 
Median age (range)- months 13.3 (1.4-49.2) 17.6(4.5-44.3) 12.3 (1.4-49.2) 0.007 
Male: female 1.3:1 1.4:1  1.3:1  0.84 
Gestational age <37 weeks at birth (%)  42  (20.8) 11 (24.4) 31  (20.1) 0.53 
Mean  (S.D.) oxygen saturation2 92.0 (4.2) 90.8 (6.0) 92.4 (3.4) 0.03 
Mean (S.D.) axillary temperature oC 37.4 (0.8) 37.6 (0.9) 37.4 (0.8) 0.18   
Bronchiolitis (%)   80 (39.6)   7 (15.6) 73 (47.4) 0.0001 
Clinical pneumonia (%) 119 (58.9) 38 (84.4) 81 (52.6) 0.0001 
Median (range) CRP-mg/l3 23 (1-435) 43 (2-435) 18 (1-405) 0.04 
Median (range) WCC x109 cells/ml4 10 (3-30) 10.2 (3-21.3)  10 (4.3-30) 0.81 
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Median (range) procalcitonin –ug/ml5 0.2 (0.1-85.1) 1.3 (0.1-85.1) 0.2 (0.1-43.0) 0.62 
Alveolar consolidation on CXR (%) 6 49 (24.3) 15 (33.3) 34 (22.1) 0.12 
Bacteria from blood culture7   7  (3.7)   7 (16.3)   0 (0)   <0.0001 
Other viruses cultured8 13 (6.4)  1 ( 2.2) 12 (7.8) 0.30 
Mean (range) hospital stay- days  3.5 (1-35) 5.8 (1-21) 4.1 (1-35) 0.003 
Case fatality rate (%)  2 (0.01)   2 (4.4)   0  (0) 0.05 
1Comparing HIV infected to HIV uninfected children. 2 Measured by a pulse oximeter in room-air upon admission to hospital. 3C-reactive protein 
(CRP) test performed in 27 HIV infected and 91 HIV uninfected children. 4Involves 10 observations in HIV infected and 19 observations in HIV 
uninfected children. WCC=white cell count.5Involved 9 observations in HIV infected and 83 observations in HIV uninfected children. 6Alveolar 
consolidation on chest radiograph using study-specific interpretation and definition criteria.(Cherian et al., 2005)7 Involved 189 observations overall, 
43 in HIV infected children and 146 in HIV uninfected children in whom blood cultures were performed. Bacteria cultured in HIV infected children 
were Streptococcus pneumoniae (n=4), Salmonellla sp. (n=2) and Streptococcus viridans (N=1). Further 20 contaminants cultured in HIV infected 
and uninfected children each.8 Other viruses identified were respiratory syncytial virus (1 in HIV infected and 8 in HIV uninfected children), and three 
influenza A virus and one adenovirus in HIV uninfected children.  
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Although more sensitive quantitative methods may be used to detect hMPV 
RNA, detecting hMPV in as low as 5 copies of RNA (Cote et al., 2003; 
Mackay et al., 2003; Maertzdorf et al., 2004), these methods require the used 
of expensive real time detection systems. Therefore the use of a nested PCR 
assay may be sufficient to detect for the presence of hMPV RNA used in the 
present study and reported elsewhere (Kaida et al., 2006). However despite 
the sensitivity of the methods used it is still possible that factors such as 
storage and transport of samples may lead to the underestimation of the 
prevalence of hMPV in the present study. 
 
The overall prevalence of hMPV RNA among the children hospitalized with 
LRTI over the study period (2000-2002) was 7.4%. Among the placebo 
vaccinated group, there were more cases of hMPV–LRTI associated 
hospitalization in HIV uninfected (11.1%) compared to HIV infected children 
(5.4%), however the overall measured incidence rate was 5.0 fold higher for 
HIV infected children than HIV uninfected, emphasizing the increase burden 
of hMPV associated LRTI in HIV-1 infected children. 
 
The overall estimated probable incidence of hMPV in HIV uninfected children 
in the present study (505-575 per 100 000) was greater than that reported by 
Peiris et al. in Hong Kong for children <6 years of age (i.e. 422 per 100 000) 
(Peiris et al., 2003). Furthermore, the present study probably underestimated 
the incidence of hMPV related hospitalizations since the estimates focused on 
hMPV-LRTI and excluded children hospitalized for non-LRTI hMPV related 
respiratory illness, e.g. asthma. Recently, Williams et al. observed that only 
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2% of children with hMPV associated LRTIs required hospitalization (Williams 
et al., 2004) suggesting that the overall incidence of hMPV-LRTI in HIV 
uninfected children may be as high as 28 750 per 100 000 children as the 
present study was limited to hospitalized children. As children with non-LRTI 
illness were not systematically investigated for respiratory viruses during the 
course of this study it is not possible to provide an estimate of the overall 
burden of hMPV associated hospitalizations. 
 
The peak period for hMPV-LRTI appeared to occur after the peak for RSV 
LRTI and preceded the peak observed for influenza virus associated LRTI in 
the years 2000 and 2001, the imbalance in sample availability between 
episodes of LRTI associated with the presence and absence of the other 
viruses, makes it difficult to draw any definite conclusions on the exact timing 
of the hMPV epidemics. Nevertheless, the data indicate that hMPV was 
identifiable throughout the year and the peak period for hMPV-LRTI 
hospitalizations occurred within the same window period when the incidence 
of hospitalization peaked for respiratory syncytial virus, influenza virus and 
parainfluenza virus associated LRTI. Similar to the findings from a Canadian 
study,(Boivin et al., 2003) the RSV epidemic was more prolonged than the 
hMPV epidemic. In addition, perennial identification of hMPV coupled with 
peak periods as identified in the present study have also been reported in 
Hong Kong and North America (Peiris et al., 2003; Williams et al., 2004). 
 
In the present study the hMPV was second to RSV as the most frequently 
identified respiratory virus in HIV uninfected children (11.1% vs. 21.1%); and 
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as common as RSV (5.1% vs. 5.4% for hMPV) in HIV infected children, thus 
highlighting it’s importance to the pathogenesis of LRTI. It is possible that the 
importance of the role of hMPV in children with LRTI compared to the other 
studied viruses may be over-estimated due to differences in the methods used 
for identifying the various viruses. Although the sensitivity of direct 
immunofluorescence testing is reported to be greater than 90% (Gardner, 
1970) the use of RT-PCR for identifying hMPV may however have resulted in 
a bias in favor of detecting hMPV. 
 
Despite identifying hMPV less frequently in HIV infected compared to HIV 
uninfected children with LRTI, the absolute burden of hMPV-LRTI was 5.0-5.4 
fold greater in HIV infected than –uninfected children This observation is in 
keeping with our findings for other respiratory viruses (Madhi et al., 2000). 
This is due to the heightened susceptibility of HIV infected children to other 
respiratory pathogens, hence, viruses being proportionately less common 
among these children compared with HIV uninfected children. The differences 
in the clinical spectrum of hMPV-LRTI observed between HIV infected and 
HIV uninfected children were similar to observations of differences in the 
clinical presentation of other respiratory viruses between HIV infected and HIV 
uninfected children (Madhi et al., 2002a; Madhi et al., 2002b; Madhi et al., 
2001). The complexity of pneumonia in HIV infected children is once again 
highlighted by the higher prevalence of bacterial co-infections including the 
broader repertoire of bacteria which cause infections in HIV infected children, 
as well as that concurrent Pneumocystis jiroveci was identified in 25% of the 
HIV infected children who were investigated for PCP. These factors may 
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explain the higher median CRP levels, longer duration of hospitalization and 
the higher mortality rate in HIV infected compared to HIV uninfected children 
hospitalized for hMPV-LRTI. The older median age of hMPV-LRTI is most 
likely due to HIV infected children remaining at risk of developing hMPV-LRTI 
beyond the age-group period when the risk of hMPV-LRTI is reduced in HIV 
uninfected children. The clinical characteristics described in Table 3.2 did not 
differ statistically between PCV and placebo recipients except for 
radiologically confirmed pneumonia. Nevertheless, the inclusion of PCV 
recipients in this analysis may have inadvertently biased the clinical 
presentation toward a milder illness as shown later in this thesis PCV 
vaccination was associated with a 58% reduction in hMPV–LRTI 
hospitalization (Chapter 5). 
 
In conclusion the present study demonstrates that the human 
metapneumovirus is a common respiratory pathogen in South Africa that is 
associated with a higher risk of LRTI associated hospitalizations among HIV 
infected than HIV uninfected. 
 
 
 
 
 
 
 
 
 63
CHAPTER 4 
MOLECULAR EPIDEMIOLOGY OF HUMAN 
METAPNEUMOVIRUS IN SOUTH AFRICA 
4.1 Human metapneumovirus genotyping 
92 (40%) of the 230 samples that tested positive for the hMPV by RT-PCR 
were randomly selected from each month for which hMPV was isolated and 
genotyped by sequencing part of the F gene using primers as described in 
chapter 2. Forty (43.4%) samples were selected from the 2000 epidemic, 34 
(37%) samples from 2001 and 18 (19.6%) samples from 2002. Due to the 
limited amount of RNA only 61 (66%) of the 92 hMPV positives were available 
for sequencing of the attachment glycoprotein (G) gene.  
 
4.2 Phylogenetics Analysis based on the sequences of hMPV 
F gene 
Phylogenetic analysis based on the partial sequences of the hMPV F gene for 
the 92 selected strains demonstrated the presence of two major genetic 
groups (A and B) and 2 subgroups (1 and 2) in South Africa during the study 
period. The presence of these groups (A and B) and subgroups (1 and 2) 
were supported by bootstrapping (bootstrap values of 100%) and the 
clustering with prototype strains from the Netherlands and Canada.  
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The nomenclature adopted in this study to classify or genotype the South 
African strains (viz: A1, A2, B1 and B2) has been used by van den Hoogen et 
al and proposed by Mackay et al as the standard nomenclature to define the 
groups and subgroups (Mackay et al., 2004; van den Hoogen et al., 2004a). 
 
Most of the strains, 56 (60.9%) clustered together with the prototype A strains 
(NL/1/00, NL/17/00, hMPV13-00 and CAN97-83) from the Netherlands and 
Canada. The remaining 36 (39.1%) strains clustered with the group B 
prototypes (NL/1/99, NL/1/94, CAN95-98 and hMPV33-01) from the 
Netherlands and Canada. Thirty eight (67.9%) of the 56 group A strains 
clustered with the group A1 prototypes from the Netherlands (NL/1/00) and 
Canada (hMPV13-00). The other 18 (32.1%) group A strains clustered with 
prototypes strains NL/17/00 and CAN97-83, representing subgroup A2. The 
majority of the group B strains (91.7%) clustered with prototype strains B2 
from the Netherlands (NL/1/94) and Canada (CAN75-98) and the other 2 
groups B strains, clustered with the subgroup B1 prototypes. 
 
From the topology of the tree (Figure 4.1) subgroup B2 was the most 
divergent and although the South African hMPV strains clustered with both 
Canadian and Netherlands prototypes, the South African subgroup A1 virus 
clustered more closely with the Canadian prototype. 
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4.3 Multiple genotypes of hMPV based on attachment 
glycoprotein (G) gene 
Phylogenetic analysis based on the sequence of the G gene supported the 
existence of two distinct genetic lineages and two sub lineages. From the 
topology of the tree (Figure 4.2) and supported by bootstrap values 70-100%, 
it appears that multiple genotypes may exist within each group as described 
for RSV (Sullender, 2000). Applying the method describe for RSV to assign 
genotypes (sequences that clustered together with bootstrap value of 70-
100% (internal nodes at the internal branches) are considered a genotype 
(Peret et al., 2000; Peret et al., 1998) to the hMPV, multiple lineages may also 
exist for hMPV. From the topology and supported by bootstrap values, 
subgroup A1 may be divided into 5 genotypes, subgroup A2 into 2 genotypes, 
B1 into 2 genotypes and B2 into 6 possible genotypes. 
 
 66
 RSA/24/01
 RSA/4/02
 RSA/36/01
 RSA/51/01
 RSA/8/02
 RSA/34/01
 RSA/19/01
 RSA/17/02
 RSA/33/01
 RSA/46/01
 RSA/30/01
 RSA/45/01
 RSA/22/02
 RSA/54/01
 RSA/31/01
 RSA/11/01
 RSA/15/01
 RSA/3/02
 RSA/21/01
 RSA/20/02
 RSA/53/01
 RSA/7/02
 RSA/1/02
 hMPV13-00
 RSA/44/01
 RSA/9/02
 RSA/10/02
 RSA/11/02
 RSA/14/02
 RSA/39/01
 NL/1/00
 RSA/44/00
 RSA/20/01
 RSA/26/00
 RSA/27/00
 RSA/20/00
 NL/17/00
 CAN97-83
 RSA/49/00
 RSA/48/00
 RSA/7/00
 RSA/7/01
 RSA/5/00
 RSA/23/02
 hMPV33-01
 RSA/21/02
 NL/1/99
 CAN75-98
 RSA/17/00
 RSA/3/00
 RSA/58/00
 RSA/37/00
 NL/1/94
 RSA/24/00
 RSA/54/00
 RSA/52/00
 RSA/90/00
 RSA/12/00
 RSA/23/00
 RSA/55/00
 RSA/29/00
 RSA/19/00
 RSA/4/00
 RSA/91/00
 RSA/15/00
 RSA/16/00
 RSA/1/00
 RSA/71/00
 RSA/93/00
100 
86
77
71 
98 
100 
100 
99 
89 
0.02  
Group A 
Group B 
1 
2 
1 
2 
 
 
 
 67
Figure 4.1. Neighbour-joining trees based on nucleotide sequences from the 
partial F gene open reading frame from 61 South African hMPV isolates. The 
trees were computed with MEGA version 2.1 using the Nucleotide: Kumira 2-
parameters (Kumar et al., 2001a). Bootstrap probabilities for 500 replicas are 
shown at the branch nodes. Only values of 70-100% are indicated. Isolates 
from South Africa are indicated by RSA followed by the isolate number and 
year (e.g. RSA/18/02). The viruses from Canada (CAN97-83, hMPV13-00, 
CAN75-98 and hMPV33-01) and the Netherlands (NL/1/00, NL/17/00, NL/1/99 
and NL/1/94) are prototypes from each subgroup. 
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Figure 4.2. Neighbour-joining trees based on nucleotide sequences from the 
G gene open reading frame from 61 South African hMPV isolates. The trees 
were computed with MEGA version 2.1 using the Nucleotide: Kumira 2-
parameters (Kumar et al., 2001a). Bootstrap probabilities for 500 replicas are 
shown at the branch nodes. Only values of 70-100% are indicated. Isolates 
from South Africa are indicated by RSA followed by the isolate number and 
year (e.g. RSA/18/02). The viruses from Canada (CAN97-83, hMPV13-00, 
CAN75-98 and hMPV33-01) and the Netherlands (NL/1/00, NL/17/00, NL/1/99 
and NL/1/94) are prototypes from each subgroup 
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4.3 Genetic diversity in the hMPV  
Genetic variability was determined by nucleotide sequencing of a 581 base 
pair fragment in the F gene and the entire G gene protein. The predicted 
amino acid sequence was determined using MEGA version 2.1 (Kumar et al., 
2001b). 
 
4.3.1 Variability of the fusion gene protein 
Only part of the F gene was sequenced, therefore the identities presented 
here are estimates of the entire gene. From the partial sequence an amino 
acid alignment presenting amino acids (44-236 of the prototype Netherlands 
strain (NL/1/00)) was compared with the prototypes as shown in Appendix 1 
(only strains that differed are shown).  
 
The estimated nucleotide and amino acid identities showed a high percentage 
identity for the F gene (Table 4.1). Between the major groups (A and B), the 
estimated identities ranged between 83-85% at the nucleotide level and 
between 93.2-95.8% at the amino acid level. Within groups (Table 4.1) 
identities ranged between 93-95% between A1-A2 and 98-100% between B1-
B2 at the nucleotide level. At the amino acid level the identities were 93.3-
97.9% between A1-A2 and 98.4% between B1-B2. 
 
Of the 92 South African hMPV that were sequenced, the predicted amino acid 
alignments are only shown for strains that differed from the Netherlands 
prototypes (Appendix 1). Within this region, between amino acid 44-236 
(corresponding to NL/1/00), cysteine residues were conserved in all South 
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African strains at position 60 and 182. Two potential conserved N linked 
glycosylation sites in the predicted F protein were observed in all the South 
Africa strains. Group specific amino acid residues were present at positions 
122, 135, 139, 167, 175 and 233 differentiating between groups A and B. 
Amino acid substitutions at various positions were exclusive to subgroups A1 
(amino acids [aa] 61, 82, 143), A2 (aa 61, 143, 185) and subgroups B1 (aa 
46, 143, 179) and B2 (aa 143).  
 
4.3.2 Variability of the G gene protein 
Sequence data showed the G gene to be high variable (Table 4.1). The G 
gene identities were 45.1-53.1% between groups at the nucleotide level and 
22.4-27.6% at the amino acid level. There was also variability within groups, 
however not as high as between groups (Table 4.1). 
 
The predicted G ORF amino acid alignments of unique South African strains 
with prototypes from Netherlands and Canada are shown in Appendix 2. 
Sequence variation due to nucleotide substitutions and insertions led to 
variable lengths in polypeptides ranging from 228 amino acid residues 
(subgroup A2) to 240 amino acid residues (subgroup B2). The hMPV G ORF’s 
of subgroups A2 and B1 terminated using the TAA codon whereas the 
subgroup B2 isolates terminated by TAG codon. For both genetic groups (A 
and B) a conserved cysteine residue was present in the intracellular domain. 
A second cysteine residue was present in all but two group B viruses 
(RSA/71/00 and RSA/90/00) were observed. 
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Table 4.1 The human metapneumovirus (hMPV) F and G gene nucleotide and 
amino acid identities of the South African strains over three consecutive years 
(2000-2002) 
 
% nucleotide (amino acid) identities 
 
 
                    
                    
Subgroups 
 
A1                                      A2                                      B1                                     B2 
 
Gene 
     
 
F 
 
A1 
 
99-100 (98.4-100) 
 
93-95 (96.3-97.9) 
 
83.8-84.1 (93.2-
94.3) 
 
82.7-84.5 (94.3-
95.8) 
          A2  99-100 (99.4-100) 83-83.8 (94.3) 83.1-85 (95.3-95.8) 
          B1   98-100 (100) 93-95 (98.4) 
          B2    96-100 (99.4) 
 
G 
 
A1 
 
95.4-100 (87.5-100) 
 
72.8-74.7 (55-63.6) 
 
45.9-47.8 (24.3-
26.2) 
 
47.4-48.7 (22.4-
26.7) 
 A2  95-100 (88.6-98.1) 50.3-51.8 (25.4-
27.7) 
51-53.1 (23.6-27.6) 
 B1   93.2 (87.9) 77.4-80.5 (58.2-
62.8) 
 B2    93.2-100 (82.8-100) 
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The predicted G ORF revealed a high serine and threonine content ranging 
from 30.7-34.9% for group A and from 30.6-36.6% for group B isolates. The 
proline content varied among the subgroups with subgroups A2 ranging from 
7.6-9.0%, A1 ranging from 9.0-9.9%, B1 from 7.8-8.7% with B2 containing the 
lowest proline content ranging from 3.7-5.2%. There was only one conserved 
potential N-linked glycosylation site that was located at the junction of the 
intracellular and transmembrane domain.  
 
The potential structure of the G protein was predicted using hydrophobicity 
plots using the procedure of Kyte and Doolittle (Kyte and Doolittle, 1982) was 
determined using Bioedit version 5.09 (Hall, 1999) for all subgroups A1, A2, 
B1 and B2 (Figure 4.3-4.6). Based on these plots the G protein has a 
transmembrane domain. Present in all subgroups was a hydrophilic N 
terminus followed by a short hydrophobic region of 20 amino acid and a C 
terminus that was predominantly hydrophilic. 
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Figure 4.3 A Hydrophobicity plot from the hMPV subgroup A1 (RSA54/01) G 
protein. The hydrophobic region is above the zero value on the y axis and 
hydrophilic below the zero value. The scale on the x axis indicates the amino 
acid residues beginning with the N-terminal. 
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Figure 4.4 A Hydrophobicity plot from the hMPV subgroup A2 (RSA7/00) G 
protein. The hydrophobic region is above the zero value on the y axis and 
hydrophilic below the zero value. The scale on the x axis indicates the amino 
acid residues beginning with the N-terminal. 
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Figure 4.5 A Hydrophobicity plot from the hMPV subgroup B2 (RSA4/00) G 
protein. The hydrophobic region is above the zero value on the y axis and 
hydrophilic below the zero value. The scale on the x axis indicates the amino 
acid residues beginning with the N-terminal. 
 
 
 
 
 
 
 
 
 77
 
 
 
 
 
 
Figure 4.6 A Hydrophobicity plot from the hMPV subgroup B1 (RSA23/02) G 
protein. The hydrophobic region is above the zero value on the y axis and 
hydrophilic below the zero value. The scale on the x axis indicates the amino 
acid residues beginning with the N-terminal.B1 RSA23/02 
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4.4 Circulation pattern of genotypes over 3 years in a single 
South African community 
All subgroups circulated over the study period, and at least two of the 4 
subgroups co-circulated in each year, with one subgroup dominating (Table 
4.2). Subgroup B2 and A2 co-circulated during the 2000 epidemic, with 72.5% 
of the circulating viruses belonging to subgroup B2. In 2001 three subgroups 
of hMPV co-circulated, A1, A2 and B2 with the majority of infections caused 
by the A1 (67.7%). Subgroup B2 viruses significantly declined (4 [11.8%] of 
34) in 2001 compared to 2000 (29 [72.5%] of 40; P<0.0001). The number of 
infections in 2002 was down and subgroup A1 and B1 co-circulated, with 
subgroup A1 responsible for 83.3% of all infections. Subgroups A2 and B2 
were not detected in 2002 
 
4.5 Discussion 
Genetic variability is a strong indicator of positive selection and affects the 
ability of a virus to continue circulating in a population. Such variability poses 
a challenge for the future development of vaccines against hMPV as 
molecular epidemiology studies, including in South Africa, indicate there to be 
a broad diversity of genetic groups in sequential epidemics. 
 
The hMPV is a novel respiratory pathogen that resembles the RSV causing 
seasonal epidemics with symptoms that are indistinguishable from RSV.  
Molecular genetic studies have shown that like RSV, there are two distinct 
genetic groups of hMPV that cause the seasonal epidemic. These studies 
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have been limited to the developed world and no studies have investigated 
the molecular epidemiology of hMPV in countries that have high prevalence of 
paediatric HIV infection. 
 
The present study reports on the largest community-based phylogenetic study 
of hMPV in Africa that examines both surface glycoproteins and provides 
evidence for the circulation of hMPV in a single African community over 3 
consecutive years. Based on phylogenetic analysis and genetic distances two 
distinct genetic groups (A and B) and subgroups (1 and 2) were found. This is 
consistent with reports from elsewhere (Bastien et al., 2004; Bastien et al., 
2003a; Boivin et al., 2002; Esper et al., 2004; Gerna et al., 2005; Mackay et 
al., 2004; Peret et al., 2004; Peret et al., 2002; van den Hoogen et al., 2004a). 
The clustering of the South African strains with strains from the Netherlands 
and Canada suggests a temporal distribution of hMPV variants. Furthermore, 
in addition to the 4 lineages (A1, A2, B1 and B2) multiple sub lineages (Huck 
et al., 2006) may exist for hMPV that needs to be characterized at the 
antigenic level and the clinical impact characterized. 
 
The existence of these two major genetic groups (A and B) and the presence 
of multiple lineages observed here and reported by others (Bastien et al., 
2004; Huck et al., 2006; Schildgen et al., 2004) impacted on the ability of 
hMPV to cause seasonal epidemics in South Africa. 
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Table 4.2 Distribution of human metapneumovirus (hMPV) genotype 
subgroups over three consecutive years (2000-2002) in a single community 
 
                                                                       Subgroups 
       
 
Year 
 
 
Total 
 
A1 
 
A2 
 
B1 
 
B2 
 
2000 
 
40 
 
0 
 
11(27.5)1 
 
0 
 
29(72.5) 
 
2001 
 
34 
 
23(67.7) 
 
7(20.5) 
 
0 
 
4(11.8) 
 
2002 
 
18 
 
15(83.3) 
 
0 
 
3(16.7) 
 
0 
 
2000-2002 
 
92 
 
38 
 
18 
 
3 
 
33 
 
1Value in parenthesis is a percentage of individual subgroups of virus in 
relation to the rest of the viruses identified in a particular year. 
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The study shows the co-circulation of both groups A and B in the same 
epidemic in a single community consistent with other reports (Boivin et al., 
2002; Esper et al., 2004; Gerna et al., 2005; Mackay et al., 2006; Mackay et 
al., 2004; Peret et al., 2004; Sarasini et al., 2006; Williams et al., 2006). 
Although all four sub-lineages were found to circulated in South Africa during 
the study they did not all co-circulate in each year as was observed in 
Australia (Mackay et al., 2006) and in Italy (Gerna et al., 2005). In South 
Africa three subgroups co-circulated in 2001 and two subgroups in other 
years. The present study showed that in 2000 subgroup B2 predominated 
(72.5% of circulating strains) but declined in 2001 (11.8% of circulating 
stains). In 2001 subgroup A1 emerged and replaced subgroup B2 as the 
predominant strain, predominating in 2001 and 2002. The emergence of B1 
strains in 2002 and its absence in previous years may have been due to pre-
existing community immunity and not to diagnostic assay limitations as was 
suggested by others (Mackay et al., 2004).  
 
The predominance of subgroup A1 during 2001 was not restricted to South 
Africa as it was also detected as the predominating circulating virus in 
Australia and Italy during the same year (Gerna et al., 2005; Mackay et al., 
2004) suggesting a global distribution in the same year. 
 
The annual change in the circulation pattern and a switch in predominating 
strains in successive years reported here and by others (Gerna et al., 2005; 
Mackay et al., 2006; Mackay et al., 2004; Peret et al., 2004) provide evidence 
that pre-existing immunity may result in a change in dominant hMPV.  
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Similar findings in changes of the dominant group of virus that emerges, 
fostered by a high prevalence of pre-existing community immunity to the other 
viral group, has been documented for RSV (Cane et al., 1994; Coggins et al., 
1998; Peret et al., 2000; Peret et al., 1998) 
 
The significance of the higher number of group A strains (60.1%) compared to 
group B strains (39.1%) detected in the present study period is unclear, but 
may be due to differences in virulence between the 2 groups or to immunity in 
the community. Several studies have proposed that group A viruses may be 
more virulent than group B virus (Esper et al., 2004; Mackay et al., 2004; 
Vicente et al., 2006), however, this observation has not been noted by others 
(Agapov et al., 2006; Ebihara et al., 2004b). An association between viral 
genotype and clinical severity cannot be made from the present study as the 
patients used in the present study were all hospitalized with LRTI.  
 
Genetic diversity may lead to antigenic variability and surface glycoproteins 
are believed to be the major neutralizing and protective antigens. To address 
the genetic variability of strains from South Africa strains the fusion gene and 
the entire attachment glycoprotein were sequenced. The F protein gene of the 
hMPV is a surface glycoprotein and believed to the major antigenic 
determinant that mediates extensive cross-lineage neutralization and 
protection (MacPhail et al., 2004; Skiadopoulos et al., 2006; Skiadopoulos et 
al., 2004). The low variability observed here for the F gene is in keeping with 
other studies that have shown it to be highly conserved (Bastien et al., 2003a; 
Biacchesi et al., 2003; Boivin et al., 2004; Peret et al., 2004; van den Hoogen 
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et al., 2004a). Further, the structural features based on the partial sequence of 
the hMPV F protein were similar to those reported by others within this region 
(between amino acids 44-236). The two potential N-linked glycosylation sites 
as well as the conserved cysteine residues at amino acid positions 60 and 
182 were also present in strains from other geographical regions (Boivin et al., 
2004) 
 
The presence of specific amino acids in the F gene that may distinguish the 
hMPV between groups appears to be universal as these specific amino acids 
have also been observed in isolates from other geographical areas (Boivin et 
al., 2004). In addition to the group and subgroup specific amino acids 
observed in the partial sequence of the F gene in the present study other 
amino acids in other regions of the F protein have also been identified as 
group differentiation markers (van den Hoogen et al., 2004a). 
 
In contrast to the F gene protein, a high degree of variation was observed for 
the G gene in this study, confirming reports by other (Biacchesi et al., 2003; 
Peret et al., 2004; van den Hoogen et al., 2004a). Most of the variation was 
observed in the extracellular domain and was due to nucleotide substitutions, 
in frame insertions and the use of alternative termination transcription codons 
(TAA or TAG) producing polypeptides of variable lengths. The high level of 
variation observed in the present study for the hMPV G gene from clinical 
samples also confirms that the variation, as observed by another study (Peret 
et al., 2004), was not due the passage of hMPV in cell culture. This high level 
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of variation particularly at the amino acid level for the G gene protein may be 
due to positive selection, which may be the result of immunological pressure.  
 
The structural features of the hMPV G protein such as the high serine-
threonine content, high proline content and a variable number of possible N-
linked glycosylation sites together with hydrophilic amino and carboxy termini 
as the observed here for both groups (A and B) are consistent with previous 
studies (Bastien et al., 2004; Peret et al., 2004; van den Hoogen et al., 2004a) 
that suggest the G attachment protein to be an anchored type II mucin like 
transmembrane protein.  
 
In summary, this is the first study to describe the molecular epidemiology of 
the hMPV over three consecutive seasons in Africa. The study shows that four 
genetic sub lineages of hMPV circulate in Africa with a switch in 
predominating group in successive seasons. The high genetic variability in the 
G gene causing amino acid changes suggests strong selective pressure.  
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CHAPTER 5  
PNEUMOCOCCAL CO-INFECTION WITH HUMAN 
METAPNEUMOVIRUS 
5.1 Study Aim  
This aspect of the study aimed at defining the minimal role of pneumococcal 
co-infection in the pathogenesis of hMPV-associated LRTI, by using PCV-9 as 
a probe to determine the role of S. pneumoniae in hMPV associated LRTI.  
Of the 202 samples that were positive for hMPV, 149 were from children that 
had been fully vaccinated per protocol; i.e. the child received all three study 
doses of vaccine within protocol defined periods. 195 children were included 
in the intent-to-treat (ITT) analysis; i.e. following receipt of the first dose of 
study vaccine. The HIV status was available for 199 (98.5%) of the 202 
children in whom hMPV was identified. 
 
5.2 The effect of pneumococcal conjugate vaccine on the 
incidence of hospitalization for hMPV-associated pneumonia 
In fully vaccinated children, the incidence of hospitalization for at least one 
episode of hMPV-associated LRTI was reduced by 46% (P = 0.0002) overall, 
45% (P=0.002) in HIV uninfected children and by 53% (P=0.035) in HIV 
infected children (Table 5.1). The intent-to-treat (ITT) estimates (Table 5.2) of 
vaccine efficacy (VE) for most of the outcomes were not significantly different 
to the estimates in the per-protocol (PP) analysis.  
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There were no differences observed in the vaccine efficacy intent-to-treat 
analysis for hMPV LRTI across the various age-groups overall (P=0.58), in 
HIV uninfected children (P=0.51) or in HIV-infected children (P=0.98). There 
was a trend to a lesser effect of the vaccine in reducing the incidence of 
hMPV-associated LRTI in vaccine recipients <6.0 months of age, compared 
with that in older children (Table 5.3). 
 
Overall there was a significant reduction in clinical pneumonia among 
vaccinees (58%; P=0.0001), in HIV uninfected children (55%; P=0.003) and in 
HIV infected children (65%; P=0.02). In addition, using the WHO criteria for 
severe/very severe pneumonia as an outcome, a 44% (P=0.003) reduction 
was observed overall, 40% (P=0.02) in HIV uninfected children and 53% 
(P=0.04) in HIV infected children (Table 5.1).  
 
5.2.1 The impact of PCV on the incidence of hMPV associated “bacterial 
pneumonia” 
The impact of PCV on the incidence of hMPV-associated “bacterial 
pneumonia” was assessed using outcomes that are more specific for 
“bacterial pneumonia”; viz radiologically confirmed pneumonia (CXR-AC) and 
LRTI associated with an elevated CRP of ≥40mg/l. 
 
5.2.1.1 Chest radiograph confirmed pneumonia 
Chest radiographs were available for 176 (90.3%) of the 195 children with 
hMPV LRTI, 134 (89.9%) of 149 HIV uninfected children and 39 (90.7%) of 43 
HIV infected. Overall a 56.0% (P=0.02) reduction in hMPV pneumonia
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Table 5.1: Percentage efficacy of pneumococcal conjugate vaccine by per protocol analysis in the prevention of human metapneumovirus 
associated respiratory tract infections. 
             Overall          HIV uninfected              HIV infected hMPV    
associated 
measured Vaccine  Placebo  Efficacy 
95%C.I. 
P 
value 
Vaccine  Placebo  Efficacy 
95%C.I. 
P 
value 
Vaccine Placebo  Efficacy 
95%C.I. 
P 
value 
LRTI1 52 97 46           
25; 62 
0.0002 41 74 45           
19; 62 
0.002 11 23 53          
3; 77 
0.035
Clinical 
pneumonia  
26 62 58           
34; 73 
0.0001 19 42 55          
22; 74 
0.003 7 20 65          
19; 85 
0.020
CXR-AC2 11            
[47]5 
25            
[88] 
56          
11; 78 
0.02 9              
[36] 
15            
[68] 
40           
-37; 74 
0.31 2             
[11] 
10           
[20] 
80          
10; 96    
0.04 
Bronchiolitis 26 35 26           
-23; 55 
0.25 22 32 31           
-18; 60 
0.17 4 3 -24         
-83;238 
0.99 
WHO severe 
pneumonia3 
41 73 44           
18; 62 
0.003 31 52 40           
7; 62 
0.02 10 21 53          
0; 78 
0.04 
CRP ≥40mg/l4 9             
[31] 
26            
[59] 
65           
26; 84 
0.007 7              
[23] 
18            
[46] 
61           
7; 84 
0.05 2             
[8] 
8             
[13]         
75          
-16; 95 
0.11 
1LRTI=lower respiratory tract infection. 2hMPV LRTI associated with alveolar consolidation on chest radiograph (CXR-AC). 3World Health 
Organization clinically diagnosed LRTI.  4hMPV LRTI with C-reactive protein (CRP) ≥40mg/l. 5Value in squared parenthesis is total number of 
the LRTI episodes for which the test was performed. 
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 associated with CXR-AC was observed (Table 5.1). There was also a 
significant reduction of 80% (P=0.04) in HIV infected children with the CXR-
AC outcome. A significant reduction was not observed (40%, P=0.31) for HIV 
ninfected children for radiologically confirmed pneumonia, but the power of the 
study to detect a significant difference of this magnitude was only 17%. 
 
5.2.1.2. LRTI associated with elevated CRP 
Overall measurements for CRP levels were available for 116 (59.5%) of the 
195 hMPV infected, 88 (59.1%) of the 149 HIV-1 uninfected children and 27 
(62.8%) of the 43 HIV-1 infected children. There was a 65% (P=0.007) 
reduction in the incidence of hMPV pneumonia with a CRP level of ≥ 40 mg/l 
in fully vaccinated recipients (Table 5.1). A significant reduction was only 
observed for the HIV uninfected (61%, P=0.05). There was no difference in 
the proportion of children tested for CRP between PCV and placebo recipients 
(Table 5.1 and 5.2).  
 
5.2.2 Effect of PCV on bronchiolitis 
A non-significant reduction in the incidence of hospitalization for hMPV-
associated bronchiolitis among vaccinees recipients in the entire study 
population (VE, 25%, P=0.21) and HIV uninfected children (VE, 25%, P=0.23) 
was observed (Table 5.2). 
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5.2.3 Coinfection with other pathogens 
Streptococcus pneumoniae was isolated from 4 (2.1%) of the 189 episodes of 
hMPV-associated LRTI for which bacterial blood cultures were performed on 
children. All of the episodes of S. pneumoniae bacteremia in children with 
LRTI occurred in HIV infected children, including 1 (6.3%) of 16 in PCV-9 
recipients and 3 (11.1%) of 27 in placebo recipients. 
 
Overall, among children investigated for all episodes (first and subsequent) of 
hMPV-associated LRTI, the prevalence of co-infection with other respiratory 
viruses was 4.1-fold (95%, CI, 1.1-18.8) greater in PCV-9 recipients (9 
[11.8%] of 76) than placebo recipients (4 [3.2%] of 126) (P=0.02). Similarly, 
HIV uninfected vaccine recipients with hMPV associated LRTI were 3.5 fold 
(95% CI, 0.9-16.4) more likely to be co-infected with other respiratory viruses 
(8[13.3%] of 60) than were placebo recipients (4 [4.3%] of 94) (P=0.06).  
In addition there was one HIV infected PCV-9 recipient with hMPV-associated 
LRTI in whom a viral co-infection was identified. 
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Table 5.2: Percentage efficacy of pneumococcal conjugate vaccine by intent-to-treat analysis in the prevention of human metapneumovirus 
associated respiratory tract infections. 
             Overall          HIV uninfected              HIV infected HMPV 
associated    
outcome  Vaccine  Placebo Efficacy 
95%C.I.
P 
value 
Vaccine  Placebo Efficacy 
95%C.I.
P 
value 
Vaccine Placebo Efficacy 
95%C.I.
P 
value 
LRTI1 72 123 42           
22; 56 
0.0002 57 92 38           
14; 56 
0.004 15 28 47           
1; 72 
0.04 
Clinical 
pneumonia 
38 78 51           
28; 67 
0.0002 27 52 48           
7; 67 
0.005 11 25 56          
12; 78 
0.02 
CXR-AC2 14            
[63]5 
33           
[113] 
58           
21; 77 
0.005 12            
[49] 
21            
[85] 
43           
-16; 72  
0.12  2            
[14] 
12           
[25] 
84           
26, 96 
0.015
Bronchiolitis 34 45 25          
-18; 52 
0.21 30 40 25           
-20; 53  
0.23      4 3 -24          
-83;237 
0.99 
WHO severe 
pneumonia3 
56 93 39           
16; 57 
0.002 42 65 35           
5; 56 
0.03 14 25 45          
-6; 71 
0.07 
CRP ≥40mg/l4 14            
[42] 
32           
[74] 
56           
18; 77 
0.008 10            
[32]          
21            
[56] 
52           
-1; 77 
0.05 4            
[10] 
10          
[17] 
60           
-26; 88 
0.17 
1LRTI=lower respiratory tract infection. 2hMPV LRTI associated with alveolar consolidation on chest radiograph (CXR-AC). 3World Health 
Organization clinically diagnosed LRTI.  4hMPV LRTI with C-reactive protein (CRP) ≥40mg/l. 5Value squared parenthesis is total number of the 
LRTI episodes for which the test was performed.   
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Table 5.3: Percentage efficacy of pneumococcal conjugate vaccine by intent-to-treat analysis in the prevention of human 
metapneumovirus associated lower respiratory tract infections by age-groups at time of hospitalization. 
             Overall          HIV uninfected children              HIV infected children Age-group 
Vaccine  Placebo  Efficacy 
95%C.I. 
P 
value 
Vaccine  Placebo  Efficacy 
95%C.I. 
P 
value 
Vaccine  Placebo  Efficacy 
95%C.I. 
P 
value 
<6.0 mo. 19 22 14        -
59; 53 
0.63 17 18 6              
-83; 51 
0.87 2 3 34            
-295;89 
0.65 
6.1-12.0 mo. 17 35 52          
14; 73   
0.012 13 27 52            
7; 75 
0.027 4 7 43            
-93; 83 
0.36 
12.1-24.0 mo. 23 38 40            
-1; 64 
0.053 20 30 33            
-17; 62 
0.16 3 7 58            
-64; 89 
0.20 
>24.0 mo. 17 31 45            
1; 70 
0.04 10 19 47            
-13; 76 
0.09 7 12 42            
-46; 77 
0.24 
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5.3 Discussion 
Animal-model and in vitro studies have shown that respiratory viral infections 
increase the susceptibility to bacterial co-infections (Beadling and Slifka, 
2004; Hament et al., 1999). Defining the role of bacterial coinfection in 
humans is hindered by the absence of sensitive tools to diagnose bacterial 
pneumonia. Experimental tools aimed at improving the sensitivity of diagnosis 
of bacterial pneumonia indicate that approximately one-third of children with 
RSV-associated pneumonia may have pneumococcal co-infections (Juven et 
al., 2000; Michelow et al., 2004). Validating the sensitivity and specificity these 
experimental assays is problematic in the absence of a reference standard 
against which they can be evaluated. 
 
Recently, Madhi and Klugman showed that 3 doses of PCV could reduce the 
incidence of hospitalization for respiratory viral associated pneumonia by 31% 
(95% CI=15-43%; P=0.00009) (Madhi and Klugman, 2004) suggesting that 
prevention of pneumococcal pneumonia by vaccination reduced the severity 
of viral infections and likelihood thereof progressing to severe pneumonia 
requiring hospitalization. By inference, superimposed bacterial infection, 
including S. pnemoniae, appear to be important in the pathogenesis of 
respiratory viral associated pneumonia.  
 
The current study suggests that bacterial co-infection, particularly S. 
pneumoniae, is an integral part in the pathogenesis of hMPV infections 
progressing to pneumonia. The estimated 58% overall reduction in clinical 
pneumonia in vaccinees provides only a conservative estimate of the 
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prevalence of pneumococcal co-infections in children with hMPV associated 
pneumonia. The true prevalence of pneumococcal co-infections in children 
with hMPV associated pneumonia may be even higher than that inferred here. 
Factors that may have resulted in under-estimating the importance of 
pneumococcal co-infections in children with hMPV associated pneumonia 
include: (i) the PCV used in our study only includes 9 of 90 different 
pneumococcal serotypes, albeit those most commonly responsible for 
invasive disease; (ii) PCV efficacy against non-bacteremic pneumococcal 
pneumonia may be less than that observed against invasive disease (83-98%) 
(Madhi and Klugman, 2004; Madhi et al., 2005b) and (iii) there may be an 
excess of non-bacteremic pneumonias due to non-vaccine pneumococcal 
serotypes in the vaccinees. 
 
The role of CRP in discriminating between viral and bacterial infections is 
controversial (Simon et al., 2004) probably due to the lack of sensitive tools 
for identification of bacterial infections, Madhi et al. reported that CRP is 
useful and improves the specificity of chest radiographs in diagnosing 
penumococcal pneumonia (Madhi et al., 2005a). The present study shows 
that PCV reduced the incidence of hMPV pneumonia when CRP levels were ≥ 
40 mg/l, suggesting that the findings by Dollner et al most likely reflected 
undiagnosed bacterial coinfection in those children (Dollner et al., 2004). In 
contrast, CRP levels have been found to be lower in children with hMPV-
associated bronchiolitis (Dollner et al., 2004; Jartti et al., 2004), providing 
indirect evidence that bacterial coinfections may be less important in children 
with bronchiolitis.  
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In summary, the findings of this study suggest that children hospitalized for 
hMPV-associated pneumonia should be treated with antibiotics to cover for 
superimposed pneumococcal infections.  
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CHAPTER 6  
REINFECTION WITH HOMOLOGOUS AND 
HETEROLOGOUS STRAIN OF HMPV 
6.1 Repeat hospitalization for hMPV associated illness 
Eight children had repeated episodes of hospitalization for hMPV associated 
illness which was spaced 30 and 307 days apart. Two of the 8 children with 
repeated episodes of hMPV hospitalization were HIV infected children and six 
were HIV uninfected. Fifteen (88.2%) of the 17 episodes of hospitalization for 
hMPV associated illness in these eight children presented as LRTI.  The ages 
of the children at first diagnosis ranged from 5.8 months to 26.5 months, with 
the second illness occurring between 30-307 days apart.  
 
Adequate samples were only available for further hMPV genotyping analyses 
in 10 of these 17 episodes and genotypes for recurrent episodes were only 
available for 4 children (1 HIV infected and three HIV uninfected).  
 
6.2 Phylogenetic analysis 
Phylogenetic analysis performed on partial F gene sequences for the 10 
strains are shown in Figure 6.1 and genotypes in Table 6.1. Nine of the 10 
strains clustered with subgroup B2 and the other with subgroup A1. Identities 
between the subgroup B2 viruses ranged from 98.9%-100%. Four of the 8 
patients had genotypes for both initial and subsequent infections.  
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Figure 6.1. Neighbour-joining trees based on nucleotide sequences from the 
partial F gene 10 South African hMPV isolates. The trees were computed with 
MEGA version 2.1 using the Nucleotide: Kumira 2-parameters (Kumar et al., 
2001a). Bootstrap probabilities for 500 replicas are shown at the branch 
nodes. Only values of 70-100% are indicated. Isolates used in the analysis for 
repeated infections are indicated by Bara (e.g. Bara01-1 refers to subject 1 in 
Table 6.1 and the virus from the 1st illness, with Bara01-2 indicating the virus 
from the 2nd illness from the same subject, etc). The viruses from Canada 
(CAN97-83, hMPV13-00, CAN75-98 and hMPV33-01) and the Netherlands 
(NL/1/00, NL/17/00, NL/1/99 and NL/1/94) are prototypes for each subgroup. 
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Table 6.1: Repeat episodes of human metapneumovirus (hMPV) associated hospitalizations in children 
N
um
ber 
Age at 1st         
episode         
(months) 
Days          
between     
episodes 
Sex GA1 HIV2          
Infection    
status 
PCV 3           
vaccination  
status 
Virus            
Subgroup      
1st/ 2nd/3rd      
episode 
First Illness                
Diagnosis 
Second Illness           
diagnosis 
Underlying 
or                  
concurrent    
illness  
1  5.8 30 M 40 Negative Placebo NA/NA4 Bronchiolitis Bronchiolitis None 
2 26.5 68 M 35 Infected Placebo B2/NA Bronchopneumonia Lobar pneumonia Ex-prem  
3  5.1 81 F 40 Negative PCV NA/B2 Bronchiolitis and       
gastroenteritis 
Bronchiolitis None 
4 10.9   92 M 40 Negative Placebo B2/B2 Lobar pneumonia Bronchiolitis None 
55 14.0 121 and  
163 
F 40 Infected PCV NA/B2/B2 Bronchopneumonia 
and gastroenteritis 
Bronchopneumonia 
 and gastroenteritis 
Pulmonary  
tuberculosi
s 
6 17.4 244 F 40 Negative PCV B2/A1 Bronchiolitis Bronchopneumonia Concurrent   
RSV              
during 1st 
illness 
7 12.8 304 F 40 Negative PCV B2/B2 Lobar pneumonia Bronchiolitis None 
8 7.4 307 M 34 Negative PCV NA/NA Bronchiolitis Asthma Ex-prem 
and                
concurrent    
RSV              
during 1st 
illness 
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Table 6.1 footnote: 1GA=gestational age at birth. 2HIV: Human 
immunodeficiency virus type-1. 3PCV=pneumococcal conjugate vaccine. 
4NA=sample not available for genotyping. 5Subject had three episodes of 
which sample were only available for the 2nd and 3rd for genotyping. Intervals 
are between the 1st and 2nd and 2nd and 3rd episodes of hospitalization when 
hMPV was identified. Diagnosis at time of 3rd episode was lymphocytic 
interstitial pneumonitis and pulmonary tuberculosis. 
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Patient 4 a male at age 10.9 months had lobar pneumonia caused by a 
subgroup B2 virus and 92 days the second episode of hMPV associated 
illness (diagnosis bronchiolitis) was also due to a virus from subgroup B2. 
Patient 5 had three episodes of hospitalization for hMPV associated illnesses.  
The first episode occurred at age 14 months with the second and third 121 
and 163 from first episode respectively. The hMPV strain causing the first 
episode could be genotyped and genotypes were only available for second 
and third episodes. The virus recovered from these 2 episodes clustered with 
subgroup B2. In addition this patient was HIV seropositive diagnosed with 
bronchopneumonia, gastroenteritis and was concurrently diagnosed with 
pulmonary tuberculosis. Patient 6, a female first episode was at age 17.4 
months caused by B2 virus was diagnosed with bronchiolitis and 
bronchopneumonia 244 days was the second episode caused by an A1 virus. 
This patient was also co-infected with RSV during the first illness. 
Patient 7 also a female was infected 304 days apart on both occasions with a 
B2 virus. 
 
6.5 Discussion 
Animal studies have shown that cross protective immunity between major 
lineages was possible (MacPhail et al., 2004; Skiadopoulos et al., 2004; van 
den Hoogen et al., 2004a). The mechanism by which re-infection occurs is not 
know but may be due to waning of immunity or the initial lack of developing 
immunity following the primary infection. Alternatively there may be prolonged 
shredding of the hMPV.  
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The present study shows that reinfection can occur within 3 months with 
either homologous or heterologous strains in both HIV uninfected and HIV 
infected children. The finding that at least two HIV uninfected children were 
hospitalized for recurrent episodes of LRTI associated with subgroup B2 virus 
with only minor differences in the percent sequence identity of the F protein 
indicate that immunity following a primary infection may be incomplete. This 
may be a result of a poor primary immune response to the viral infection, or of 
waning immunity as these episodes occurred between 92 and 304 days apart. 
Another possibility is prolonged shedding in the subject in whom the episodes 
occurred 92 days apart - for which there was 99.8% identity in the nucleotide 
sequence of studied F protein of the virus identified in each of the episodes. 
The subject with repeat hMPV episodes that occurred 304 days apart, for 
which there was 98.9% identity of the F protein nucleotide sequence studied, 
had two additional episodes of hospitalization for respiratory tract infections 
between these episodes for which nasopharyngeal samples tested negative 
for hMPV, making repeat infections rather than prolonged shedding more 
likely in this subject. The repeat episodes of hMPV-associated hospitalization 
in an HIV infected child with 3 episodes (subject 5 in Table 6.1), especially 
documentation of subgroup B2 virus on the second and third episodes for 
which there was 100% homology in the nucleotide sequence of the F protein 
indicates that identification of hMPV in this child may have been due to 
prolonged shedding of the virus for at least 163 days. Falsey et al. have in 
contrast reported that hMPV was not detected more than 14 days after onset 
of illness in otherwise healthy individuals (Falsey et al., 2006). 
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Re-infection with heterologous strains of hMPV has been reported in an 
immunocompromized child (Pelletier et al., 2002) and recently in a 9 month 
old child who had repeat infections one month apart (Ebihara et al., 2004a). 
Williams et al. reported heterologous hMPV re-infections in a 20 year follow-
up study of children with upper respiratory tract infections, as well as two 
children with homologous re-infection due to subgroup B1 and A2 hMPV 
(Williams et al., 2006). Williams et al. also suggested that primary immunity 
induced following hMPV infection of the LRTI reduced subsequent infections 
in lower respiratory tract and limited the replication of hMPV to the upper 
respiratory tract. In contrast the present study which is limited to children with 
LRTI shows that subsequent infections may also occur in the lower respiratory 
tract. Although the immune response to hMPV infections is unclear for 
humans, animal studies using BALB/c mouse model indicate that the cytotoxic 
T lymphocyte and antibody response to hMPV infection is delayed (Alvarez 
and Tripp, 2005). 
 
In conclusion, the data suggest that similar to RSV (Scott et al., 2006) re-
infection can occur with homologous and heterologous strains of hMPV and 
that prior infection with hMPV is not adequate to protect against subsequent 
infections in some children.  
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CHAPTER 7  
STUDY LIMITATIONS 
The limitations of this study may be due either to molecular or clinical aspects 
and will be discussed below. 
  
7.1 Molecular limitations 
The prevalence of the hMPV-associated LRTI may be underestimated in this 
study probably due the collections, transport as well as the method for 
identification of hMPV used in this study. RNA is unstable and it is possible 
that the transport and storage of NPAs could have compromised the RNA 
yields and detection of true positives despite the use of a sensitive nested RT-
PCR approach. Using a nested PCR approach you also run the risk of 
detecting false positives due to contamination. To reduce the risk of 
contamination, RNA isolation, primary RT-PCR and nested PCR were 
performed in separate laboratories. Further to control for false positives and to 
examine the specificity of the primers, hMPV positives were sequenced. 
 
Although a significant number (40% of all hMPV positives) of hMPV were 
sequenced it still possible that the distribution of the genotypes may be biased 
thus affecting the conclusions on the circulation pattern over the course of the 
study. Another limitation may be the design of the primers, however, it is 
unlikely that this could have any effect on the study as similar results were 
obtained from sequencing and phylogenetic analysis of the both surface 
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glycoproteins, i.e. for example, samples that were genotyped as belonging to 
A1 for the F gene were confirmed as A1 for the G gene. 
 
The present study also describes the F gene to be highly conserved based on 
the identities from the partial sequences of this gene. Although the entire F 
gene was not sequenced a study by van den Hoogen et al. showed that 
similar identities could be obtained from partial and full length sequencing of 
the F gene (van den Hoogen et al., 2004a). 
 
7.2 Clinical limitations  
Although samples were available for hMPV testing in the majority of HIV 
infected and HIV uninfected children, the differences observed between LRTI 
episodes for which samples were and were not available may have some 
implications regarding the study conclusions. These include that younger 
children with hMPV may have been missed and this may have 
underestimated the incidence of hMPV-LRTI in our population since hMPV 
illness is more common during infancy (Williams et al., 2004). The reasons for 
the unavailability of samples in this study may be due to: i. smaller volumes of 
saline being used and/or retrieved when that aspirates were performed in very 
young children; ii. most of the retrieved sample may have been used for 
identifying specific viruses once the pooled respiratory virus screening test 
indicated the presence of one of the viruses which were being studied 
prospectively; and this more commonly occurred in younger children.  
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The prevalence of co-infections with other respiratory viruses may have been 
under-reported in this thesis and may be due to the different methods used for 
detection of other viruses. Co-infection may be particularly important 
regarding the duration of hospitalization and outcome of subjects since, 
although controversial,(Lazar et al., 2004) dual infections with RSV have been 
found to result in more severe disease (Greensill et al., 2003; Konig et al., 
2004). The lack of any difference in the duration of hospitalization or case 
fatality rate of those LRTI episodes for which samples were and were 
unavailable among HIV infected and HIV-uninfected children in this study 
however makes this unlikely. Nevertheless, the differences observed in this 
study between tested and untested episodes of LRTI highlights the problem 
associated with drawing conclusions and making comparisons with the many 
other retrospectively conducted studies which may also have been biased in 
their findings based on the samples available for hMPV testing.  
 
Limitations of the study include differences in the ages of subjects and in the 
prevalence of other respiratory viruses in those LRTI episodes for which 
nasopharyngeal samples were unavailable for hMPV testing. It is, therefore 
possible that the vaccine efficacy in younger children may be lower than that 
observed in the overall population, as suggested by the age group analysis in 
Table 5.3. Possible explanations for this lesser effect in young children may 
be due to the following: 1) hMPV is an independent cause of severe LRTI in 
very young infants; 2) PCV is less able to protect against pneumococcal 
pneumonia in very young infants, since some may not have completed their 
full series of primary vaccination; and 3) coinfections with other viruses, 
 105
especially RSV which commonly infects infants <6.0 months of age may also 
result in severe LRTI (Cuevas et al., 2003; Greensill et al., 2003). That the 
latter may occur independently of pneumococcal coinfection is indirectly 
supported by in this study, in children hospitalized with hMPV-associated 
LRTI, the prevalence of coinfection with other respiratory viruses was 4.1 
greater among PCV recipients than placebo, suggesting that viral coinfection 
may have been involved in the pathogenesis of severe hMPV-LRTI among 
the PCV recipients. Since some specimens from younger children were 
unavailable for hMPV testing, the bias introduced by the exclusion of those 
samples may have led to a conservative estimate of the association between 
hMPV and other viral pneumonias. 
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CHAPTER 8 
CONCLUDING REMARKS 
Human metapneumvirus was initially isolated from nasopharyngeal aspirates 
collected from 28 children in the Netherlands with respiratory tract infections 
(van den Hoogen et al., 2001). The virus was illusive prior to 2001 due to its 
specific cell culture requirements, but has been circulation in humans for at 
least 50 years (van den Hoogen et al., 2001).  
 
Although not an emerging pathogen in the true sense, the hMPV is still new 
and the epidemiology is still being investigated. Following, its initial isolation 
the hMPV has been shown to circulate worldwide and isolated as the major 
cause of upper and lower respiratory tract infections. Clinically it is 
indistinguishable from RSV, and is second to RSV as the cause of RTI. Its 
seasonality overlaps with RSV and appears to cause infections in children 
that are older than RSV. 
 
The common respiratory viruses such as RSV, influenza A/B, parainfluenza 
types 1-3 have been shown to have a major impact on the morbidity and 
mortality of HIV in South Africa (Madhi et al., 2001). The present thesis 
describes the molecular epidemiology of the hMPV in South Africa and 
examines the impact it has on the burden of disease in HIV infected and 
uninfected children.  
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Using PCR as a diagnostic tool, the hMPV RNA was detected overall in 7.4% 
of children hospitalized with LRTI’s, of which 9.1% where HIV uninfected and 
4.5% HIV infected. The mean age of children with hMPV-LRTI was 13.3 
months and hMPV-LRTI occur at an early age in HIV uninfected (12.3 
months) than HIV infected children (17.6 months; P=0.007). The overall 
measured incidence rate of hMPV-LRTI was higher for HIV infected children 
than HIV uninfected despite hMPV being a less common cause of LRTI in HIV 
infected children compared to HIV uninfected children, a finding in keeping 
with studies of other respiratory viruses in South Africa (Madhi et al., 2000). 
Similarly, hMPV disease was shown be more severe in HIV infected children 
than HIV uninfected children. There was higher mortality rate (4.4 vs 0%; 
P=0.05) and longer duration of hospitalization (5.8 vs. 4.1 days, P=0.003) for 
HIV infected children compared to HIV uninfected. HIV infected children were 
more likely to have concurrent bacteremia (16.3% vs. 0%, P<0.0001), had 
higher median CRP levels (P=0.01) therefore more likely to be co-infected 
with bacteria and were more likely to present with pneumonia than 
bronchiolitis (P=0.0001). In addition, Pneumocystis jiroveci pneumonia (PCP) 
was diagnosed in two (25%) of eight HIV infected children with hMPV-LRTI in 
whom an immunofluorescence assay was performed to identify Pneumocystis 
jiroveci cysts.  
 
hMPV was as common as RSV in being identified in HIV infected children with 
pneumonia and was second to RSV as the most frequent virus identified in 
HIV uninfected children. Similar to RSV, it was shown capable of causing 
repeated infections as described in Chapter 6. This chapter shows that prior 
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infection with hMPV is not sufficient to prevent from subsequent infections, 
even within the same season. The study reports that the hMPV is capable 
causing repeated infections in a space of 3 months by either homologous or 
heterologous strains. 
 
Pneumococcal co-infections were also shown to be an essential part of the 
pathogenesis of most severe hMPV infections progressing to pneumonia. 
Using PCV as a probe to define the role of pneumococcocal coinfections as 
described in Chapter 5. The study observed a 58% reduction (58%) in clinical 
pneumonia among hMPV infected children that were given PCV compared to 
hMPV infected children that were given the placebo (P-0.0001). PCV also had 
an impact on hMPV associated bacterial pneumonia as overall a 56.0% 
(P=0.02) reduction in hMPV pneumonia associated with CXR-AC was 
observed and a 65% (P=0.007) reduction in the incidence of hMPV 
pneumonia with a CRP level of ≥ 40 mg/l in fully vaccinated recipients was 
also observed. The present study also demonstrates that coinfection of hMPV 
with pneumococci in children >6 months of age progressed to pneumonia that 
necessitates hospitalization. An implication of this observation is that children 
hospitalized for hMPV-associated pneumonia should be treated with 
antibiotics.  
 
In South Africa, hMPV had a perennial circulation, peaking during the autumn-
winter months after the RSV peak season and prior to the influenza and 
parainfluenza peak season. The molecular epidemiology as examined in 
Chapter 4 provides evidence for the ability of the hMPV to survive and cause 
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annual epidemics. The study shows that all subgroups circulate in South 
Africa and that annual epidemics were caused by the switching of 
predominating hMPV strains in subsequent years (B2 in 2000 to A2 in 2001). 
Further sequence of the two surface glycoproteins demonstrated that the 
fusion gene protein (F gene) was conserved whereas the attachment 
glycoprotein (G) was highly variable particularly in the extracellular domain 
suggestive of positive selection probably due to immunological pressure. 
Therefore, the F gene may be a target for a vaccine as it is conserved and 
has been shown to be the major neutralization antigen that confers substantial 
neutralization and protection across lineages (Skiadopoulos et al., 2006). 
 
In conclusion the hMPV is also a major cause of LRTI among children in 
South Africa and can be added to the vast list of pathogens that can cause 
pneumonia thus impacting on the HIV epidemic in sub-Saharan Africa.  
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APPENDICES 
APPENDIX 1: AMINO ACID ALIGNMENT OF FUSION PROTEIN 
Alignment of the F proteins of representative samples of SA hMPV isolates 
and prototype sequences from the Netherlands (NL/1/00, NL/1/99, NL/1/94 
and NL/17/00) and Canada (hMPV13-00, CAN97-83, hMPV33-01 and 
CAN75-98). Only amino acid residues that differed from the Netherlands 
prototypes for each subgroup are shown and identical amino acids are 
represented by periods and dashes indicate gaps. The proposed fusion 
domain is indicated in bold. Potential glycosylation sites are underlined. 
Numbers indicate the amino acid position in the F open reading frames 
corresponding to the Netherlands prototype isolates 
 
A1.1 hMPV Group A1 
NL/1/00         YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
hMPV13-00       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/9/02        YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/39/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/14/02       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/10/02       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/11/02       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/1/02        YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/44/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/7/02        YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/53/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/20/02       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/21/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/3/02        YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/8/02        YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/33/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/19/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/4/02        YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/11/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/34/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/24/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/51/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/22/02       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/46/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/30/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/45/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/15/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/17/02       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/36/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/31/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
RSA/54/01       YTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRF 60 
                ************************************************************ 
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NL/1/00         VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
hMPV13-00       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/9/02        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/39/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/14/02       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/10/02       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/11/02       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/1/02        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/44/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/7/02        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/53/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/20/02       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/21/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/3/02        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/8/02        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/33/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/19/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/4/02        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/11/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/34/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/24/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/51/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/22/02       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/46/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/30/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/45/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/15/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/17/02       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/36/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/31/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/54/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVR 120 
                ************************************************************ 
 
NL/1/00         ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
hMPV13-00       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRKVLNVVRQFSDNAGITPAISLDLMT 180 
RSA/9/02        ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/39/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/14/02       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/10/02       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/11/02       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/1/02        ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/44/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/7/02        ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/53/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/20/02       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/21/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/3/02        ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/8/02        ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/33/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/19/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/4/02        ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/11/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/34/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/24/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPSISLDLMT 180 
RSA/51/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/22/02       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/46/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/30/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/45/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/15/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/17/02       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/36/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/31/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/54/01       ELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
                ***********************************  *************** ******* 
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NL/1/00         DAELARAVSNMPT 193 
hMPV13-00       DAELARAVSNMPT 193 
RSA/9/02        DAELARAVSNMPT 193 
RSA/39/01       DAELARAVSNMPT 193 
RSA/14/02       DAELARAVSNMPT 193 
RSA/10/02       DAELARAVSNMPT 193 
RSA/11/02       DAELARAVSNIAT 193 
RSA/1/02        DAELARAVSNMPT 193 
RSA/44/01       DAELARAVSNMPT 193 
RSA/7/02        DAELARAVSNMPT 193 
RSA/53/01       DAELARAVSNMPT 193 
RSA/20/02       DAELARAVSNMPT 193 
RSA/21/01       DAELARAVSNMPT 193 
RSA/3/02        DAELARAVSNMPT 193 
RSA/8/02        DAELARAVSNMPT 193 
RSA/33/01       DAELARAVSNMPT 193 
RSA/19/01       DAELAIAVSNMPT 193 
RSA/4/02        DAELARAVSNMPT 193 
RSA/11/01       DAELARAVSNMPT 193 
RSA/34/01       DAELARAVSNMPT 193 
RSA/24/01       DAQLARAVSNMPT 193 
RSA/51/01       DAELARAVSNMPT 193 
RSA/22/02       DAELARAVSNMPT 193 
RSA/46/01       DAELARAVSNMPT 193 
RSA/30/01       DAELARAVSNMPT 193 
RSA/45/01       DAELARRVSNMPT 193 
RSA/15/01       DAELARAVSNMPT 193 
RSA/17/02       DAELARAVSNMPT 193 
RSA/36/01       DAELARAVSNMPT 193 
RSA/31/01       DRELARAVSNMPT 193 
RSA/54/01       DAELARAVSNMPT 193 
                *  **  ***  * 
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A1.2 hMPV GROUP A2 
NL/17/00        YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
CAN97-83        YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/7/00        YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/7/01        YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/5/00        YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/26/00       YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/20/01       YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/44/00       YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/27/00       YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/20/00       YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/48/00       YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/49/00       YTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
                ************************************************************ 
 
NL/17/00        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
CAN97-83        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/7/00        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/7/01        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/5/00        VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/26/00       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/20/01       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/44/00       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/27/00       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/20/00       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/48/00       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/49/00       VLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVR 120 
                ************************************************************ 
 
NL/17/00        ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
CAN97-83        ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/7/00        ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/7/01        ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/5/00        ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/26/00       ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/20/01       ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/44/00       ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/27/00       ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/20/00       ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/48/00       ELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/49/00       ELKNFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
                *** ******************************************************** 
 
NL/17/00        DAELARAVSNMPT 193 
CAN97-83        DAELARAVSNMPT 193 
RSA/7/00        DAELARAVSNMPT 193 
RSA/7/01        DAELARAVSNMPT 193 
RSA/5/00        DAELARAVSNMPT 193 
RSA/26/00       DAELARAVSNMPT 193 
RSA/20/01       DAELARAVSNMPT 193 
RSA/44/00       DAELARAVSNMPT 193 
RSA/27/00       DAELARAVSNMPT 193 
RSA/20/00       DAELARAVSNMPT 193 
RSA/48/00       DAELARAVSNMPT 193 
RSA/49/00       DAELARAVSNMPT 193 
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A1.3 hMPV Group B1 
RSA/21/02       YTYVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/23/02       YTYVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
NL/1/99         YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
hMPV33-01       YINVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
                *  ********************************************************* 
 
RSA/21/02       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKQTNEAVSTLGNGVRVLATAVR 120 
RSA/23/02       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKQTNEAVSTLGNGVRVLATAVR 120 
NL/1/99         VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKQTNEAVSTLGNGVRVLATAVR 120 
hMPV33-01       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKQTNEAVSTLGNGVRVLATAVR 120 
                ************************************************************ 
 
RSA/21/02       ELKEFVSKNLTSAINRNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/23/02       ELKEFVSKNLTSAINRNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
NL/1/99         ELKEFVSKNLTSAINRNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
hMPV33-01       ELKEFVSKNLTSAINRNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
                ************************************************************ 
 
RSA/21/02       DAELARAVSYMPT 193 
RSA/23/02       DAELARAVSYMPT 193 
NL/1/99         DAELARAVSYMPT 193 
hMPV33-01       DAELARAVSYMPT 193 
                ************* 
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A1.4 hMPV Group B2 
NL/1/94         YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
CAN75-98        YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/1/00        YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/4/00        YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/91/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/19/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/16/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/15/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/71/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/93/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/29/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/55/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/23/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/12/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/90/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/54/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/52/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/24/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/17/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/3/00        YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/58/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
RSA/37/00       YTNVFTLEVGDVENLTCTDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRF 60 
                ************************************************************ 
 
NL/1/94         VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
CAN75-98        VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/1/00        VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/4/00        VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/91/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/19/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/16/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/15/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/71/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/93/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/29/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/55/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/23/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/12/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/90/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/54/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/52/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/24/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKTTNEAVSTLGNGVRVLATAVR 120 
RSA/17/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/3/00        VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/58/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKKTNEAVSTLGNGVRVLATAVR 120 
RSA/37/00       VLGAIALGVATAAAVTAGIAIAKTIRLESEVNAIKGALKKTNEAVSTLGNGVRVLATAVR 120 
                *************************************** ******************** 
 
NL/1/94         ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
CAN75-98        ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/1/00        ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/4/00        ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/91/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/19/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/16/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/15/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/71/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/93/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/29/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/55/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/23/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/12/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/90/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/54/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/52/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/24/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/17/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/3/00        ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/58/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
RSA/37/00       ELKEFVSKNLTSAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMT 180 
                ************************************************************ 
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NL/1/94         DAELARAVSYMPT 193 
CAN75-98        DAELARAVSYMPT 193 
RSA/1/00        DAELARAVSYMPT 193 
RSA/4/00        DAELARAVSYMPT 193 
RSA/91/00       DAELARAVSYMPT 193 
RSA/19/00       DAELARAVSYMPT 193 
RSA/16/00       DAELARAVSYMPT 193 
RSA/15/00       DAELARAVSYMPT 193 
RSA/71/00       DAELARAVSYMPT 193 
RSA/93/00       DAELARAVSYMPT 193 
RSA/29/00       DAELARAVSYMPT 193 
RSA/55/00       DAELARAVSYMPT 193 
RSA/23/00       DAELARAVSYMPT 193 
RSA/12/00       DAELARAVSYMPT 193 
RSA/90/00       DAELARAVSYMPT 193 
RSA/54/00       DAELARAVSYMPT 193 
RSA/52/00       DAELARAVSYMPT 193 
RSA/24/00       DAELARAVSYMPT 193 
RSA/17/00       DAELARAVSYMPT 193 
RSA/3/00        DAELARAVSYMPT 193 
RSA/58/00       DAELARAVSYMPT 193 
RSA/37/00       DAELARAVSYMPT 193 
                ************* 
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APPENDIX 2: AMINO ACID ALIGNMENT OF THE G PROTEIN 
Alignment of the G proteins of representative samples of SA hMPV isolates 
and prototypes sequences from the Netherlands (NL/1/00, NL/1/99, NL/1/94 
and NL/17/00) and Canada (hMPV13-00, CAN97-83, hMPV33-01 and 
CAN75-98). Only amino acid residues that differed from the Netherlands 
prototypes for each subgroup are shown and identical amino acids are 
represented by periods and dashes indicate gaps. The proposed intracellular, 
transmembrane and extracellular domains are indicated by arrows above the 
alignment. Potential N-linked glycosylation sites are underline. Numbers 
indicate the amino acid position in the G open reading frames corresponding 
to the Netherlands prototype isolates 
 
A2.1 hMPV subgroup A1 
                     Intracellular ><    Transmembrane  >< Extracellular 
NL/1/00         IDMLKARVKNRVARSKCFKNASLVLIGITTLSIALNIYLIINYKMQKNTSESEHHTSSSP 70 
RSA/54/01       .......L...............I......................E............. 70 
RSA/30/01       ............................................................ 70 
RSA/8/02        ............................................................ 70 
RSA/20/02       ..............................................K............. 70 
RSA/22/02       ..............................................E............. 70 
RSA/33/01       ............................................................ 70 
RSA/7/02        ............................................................ 70 
RSA/53/01       ............................................................ 70 
RSA/17/02       ............................................................ 70 
RSA/3/02        ............................................................ 70 
RSA/4/02        ............................................................ 70 
hMPV13-00       .......V...................................T................ 70 
RSA/21/01       ...........................................K................ 70 
RSA/19/01       ............................................................ 70 
RSA/31/01       ............................................................ 70 
RSA/34/01       ............................................................ 70 
RSA/36/01       ..........................................H................. 70 
RSA/10/02       ..........................................YT................ 70 
RSA/14/02       ............................................................ 70 
RSA/11/02       ............................................................ 70 
RSA/9/02        ............................................................ 70 
RSA/1/02        ............................................................ 70 
RSA/44/01       ............................................................ 70 
                ******* *************** ******************  ** ************* 
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NL/1/00         MESSRETPTVPTDNSDTNSSPQHPTQQSTEGSTLYFAASASSPETEPTSTPDTTNRPPFV 130 
RSA/54/01       ..................PGS.Y...........H..................AS..L.. 130 
RSA/30/01       ............................................................ 130 
RSA/8/02        ..................................................L......... 130 
RSA/20/02       ..................................................P......... 130 
RSA/22/02       .............................G.....P........................ 130 
RSA/33/01       .............................E.....F.................T...... 130 
RSA/7/02        ............................................................ 130 
RSA/53/01       ............................................................ 130 
RSA/17/02       ...............................F............................ 130 
RSA/3/02        ............................................................ 130 
RSA/4/02        ...............................S............................ 130 
hMPV13-00       .........................................................P.. 130 
RSA/21/01       ....................................V....................L.. 130 
RSA/19/01       ....................................A....................... 130 
RSA/31/01       ......................H..................................... 130 
RSA/34/01       ...............................................I............ 130 
RSA/36/01       ..........L...........Y........................T............ 130 
RSA/10/02       ..........PM..........H............S...T...G......S......PL. 130 
RSA/14/02       ............................................................ 130 
RSA/11/02       ............................................................ 130 
RSA/9/02        .........................................................A.. 130 
RSA/1/02        ......................Y............F.......E.............PF. 130 
RSA/44/01       .......................................A.................... 130 
                **********  ******   * ****** * **   ** *** *** ** **  **  * 
 
NL/1/00         DTHTTPPSASRTKTSPAVHTKNNPRTSSRTHSPPRATTRTARRTTTLRTSSTRKRPSTAS 190 
RSA/54/01       ............R..........L.I.P......W.M...V.G........I.....A.. 190 
RSA/30/01       ............................................................ 190 
RSA/8/02        ...................................................T........ 190 
RSA/20/02       ............................................................ 190 
RSA/22/02       .......................P...............................L.... 190 
RSA/33/01       .......................L...........................I...P.... 190 
RSA/7/02        ............................................................ 190 
RSA/53/01       ............................................................ 190 
RSA/17/02       ............................................................ 190 
RSA/3/02        ...................................................T........ 190 
RSA/4/02        .......................P...........................I........ 190 
hMPV13-00       .......................LK................................T.. 190 
RSA/21/01       ........................R................................... 190 
RSA/19/01       ..................Y....P....K............................... 190 
RSA/31/01       ..................H....L.T..R..................H...T........ 190 
RSA/34/01       ...............................................R............ 190 
RSA/36/01       .......................P.................................... 190 
RSA/10/02       .........................I......S...T....................... 190 
RSA/14/02       ................................P........................... 190 
RSA/11/02       ............................................................ 190 
RSA/9/02        ............................................................ 190 
RSA/1/02        ...................................................I........ 190 
RSA/44/01       ............K............T.................................. 190 
                ************ ***** ****   *  *** * * *** * **** *** *** * ** 
 
NL/1/00         VQPDISATTHKNEEASPASPQTSASTTRIQRKSVEANTSTTYNQT 235 
RSA/54/01       ....S......H....SV........A.P...------------- 222 
RSA/30/01       ................P...............------------- 222 
RSA/8/02        ................................------------- 222 
RSA/20/02       ................................------------- 222 
RSA/22/02       ................................------------- 222 
RSA/33/01       ................................------------- 222 
RSA/7/02        .......................-N.......------------- 221 
RSA/53/01       .......................AS.......------------- 222 
RSA/17/02       ................................------------- 222 
RSA/3/02        ................................------------- 222 
RSA/4/02        ................................------------- 222 
hMPV13-00       ......T.........................GMEASTSTTHNQT 235 
RSA/21/01       .R....A.........................------------- 222 
RSA/19/01       .Q..............................------------- 222 
RSA/31/01       ................................------------- 222 
RSA/34/01       ................................------------- 222 
RSA/36/01       ......................P.........------------- 222 
RSA/10/02       ......................S.......GR------------- 222 
RSA/14/02       ................................------------- 222 
RSA/11/02       ...........Q....................------------- 222 
RSA/9/02        ...........H....................------------- 222 
RSA/1/02        ................................------------- 222 
RSA/44/01       ................................------------- 222 
                * ** * **** ****  ****   * * *                
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A2.2 hMPV subgroup A2 
        Intracellular ><    Transmembrane  >< Extracellular 
NL/17/00        VKNRVARSKCFKNASLILIGITTLSIALNIYLIINYTIQKTTSESEHHTSSPPTEPNKEA 77 
RSA/7/00        .......................................................S.... 77 
RSA/26/00       .........................M.................................. 77 
RSA/27/00       .........................I.................................. 77 
RSA/7/01        .......................................................P.... 77 
RSA/20/01       .......................................................S.... 77 
RSA/44/00       ............................................................ 77 
RSA/5/00        ............................................................ 77 
RSA/48/00       ............................................................ 77 
RSA/49/00       ............................................................ 77 
CAN97-83        .........................................S.................. 77 
RSA/20/00       .....................................M...T.................. 77 
                ************************* *********** *** ************* **** 
 
NL/17/00        STISTDNPDINPSSQHPTQQSTENPTLNPAASASPSETEPASTPDTTNRLSSVDRSTAQP 137 
RSA/7/00        ............N...S........................................... 137 
RSA/26/00       ............................................................ 137 
RSA/27/00       .....N...................................................... 137 
RSA/7/01        .....................................I..............A....... 137 
RSA/20/01       .....................................T..............V....... 137 
RSA/44/00       ......................................................S..... 137 
RSA/5/00        ....................Y.................................R..... 137 
RSA/48/00       ....................S.........................I........P.... 137 
RSA/49/00       ..............................................T........S.... 137 
CAN97-83        ................P...............V........................... 137 
RSA/20/00       ................................A...................A....... 137 
                ***** ****** *** *** *********** **** ******** ***** *  **** 
 
NL/17/00        SESRTKTKPTVHTINNPNTASSTQSPPRTTTKAIRRATTFRMSSTGKRPTTTLVQSDSST 197 
RSA/7/00        ..........A..R...S....I.....A..........L.................... 197 
RSA/26/00       .......E..V...........T.L................................... 197 
RSA/27/00       .......................................F.................... 197 
RSA/7/01        ..............................M.....................P......I 197 
RSA/20/01       ........................F.....T.....................S......T 197 
RSA/44/00       ....A..............T.....S..........................L....... 197 
RSA/5/00        ....T..K........S..S.....P..........................S....... 197 
RSA/48/00       ...................A.....Q..........................L....... 197 
RSA/49/00       ........................SP.................................. 197 
CAN97-83        ................P...................................S....... 197 
RSA/20/00       ........L..............................L.T..........P....I.. 197 
                **** **  * ** **  * ** *  ** * ******** * ********** **** *  
 
NL/17/00        TTQNHEETGSANPQASASTMQN--------- 219 
RSA/7/00        ................V.....QHTNNTKPN 211 
RSA/26/00       ......................QHTNNTKPN 211 
RSA/27/00       ......................QHTNNTKPN 211 
RSA/7/01        ................A.....QHTNNTKPN 211 
RSA/20/01       ..........T.....V.....QHTNNTKPN 211 
RSA/44/00       ..........A...........QHTNNIKPS 211 
RSA/5/00        ................A.....QHTNNIKPN 211 
RSA/48/00       ......................QHTNNIKPN 211 
RSA/49/00       ...................I..QHTNNIKPN 211 
CAN97-83        ................V..M..HTNN-IKPN 210 
RSA/20/00       ................A.....--------- 202 
                ********** ***** ** **          
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A2.3 hMPV subgroup B1 
               Intracellular ><    Transmembrane   >< Extracellular 
NL/1/99         SRCYRNATLILIGLTALSMALNIFLIIDHATLRNMIKTENCANMPSAEPSKKTPMTSTAG 84 
hMPV33-01       ............................................................ 84 
RSA/23/02       ............................................................ 84 
RSA/21/02       .............................................P.........I.... 84 
                ********************************************* ********* **** 
 
NL/1/99         PNTKPNPQQATQWTTENSTSPVATPEGHPYTGTTQTSDTTAPQQTTDKHTAPLKSTNEQI 144 
hMPV33-01       .S...................A..L......E....P...........Y..LS....... 144 
RSA/23/02       ...............................G................H...P....... 144 
RSA/21/02       .N......................P....H.............................. 144 
                * ******************* ** **** * **** *********** **  ******* 
 
NL/1/99         TQTTTEKKTIRATTQKREKGKENTNQTTSTAATQTTNTTNQIRNASETITTSDRPRTDTT 204 
hMPV33-01       .......K.T...P.R.K.......Q..............................I.I. 204 
RSA/23/02       .......R.....TPKKG.R.....P..............................T.T. 204 
RSA/21/02       .......K......QRRE.......Q................K..I............S. 204 
                ******* * ***     * ***** **************** ** ********** * * 
 
NL/1/99         TQSSEQTTRATDPSSPPHHA------- 224 
hMPV33-01       ...........E.GF.....RRGAGPR 231 
RSA/23/02       ..........A...SS.Y..RRGAGPR 231 
RSA/21/02       ..........TD.S.P.HR.QGSAKPK 231 
                **********  *   *  *        
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A2.4 hMPV subgroup B2 
                 Intracellular ><      Transmembrane  >< Extracellular 
NL/1/94         SSKCYRNATLILIGLTALSMALNIFLIIDYAMLKNMTKVEHCVNMPPVEPSKKTPMTSAV 60 
CAN75-98        ..............S................TS........................... 60 
RSA/4/00        ..............L.................L..V........................ 60 
RSA/29/00       ............................................................ 60 
RSA/90/00       .........................................W.................. 60 
RSA/71/00       ............................................................ 60 
RSA/12/00       .........................................C............L..... 60 
RSA/23/00       ............................................................ 60 
RSA/54/00       ...................................M..................P..... 60 
RSA/93/00       ............................................................ 60 
RSA/24/00       ............................................................ 60 
RSA/3/00        ...............................M..........I................. 60 
RSA/17/00       ............................................................ 60 
RSA/37/00       ..........................................V................. 60 
                ************** ****************  ** *****  *********** ***** 
 
NL/1/94         DLNTKPNPQQATQLAAEDSTSLAATSEDHLHTGTTPTPDATVSQQTTDEYTTLLRSTNRQ 120 
CAN75-98        .P............TT.........L.......................H......T... 120 
RSA/4/00        .L...L...................S.N.......Q.S...I..............I... 120 
RSA/29/00       ............................................................ 120 
RSA/90/00       ....................................I....................... 120 
RSA/71/00       ............................................................ 120 
RSA/12/00       ................................................K........... 120 
RSA/23/00       ................................................E........... 120 
RSA/54/00       .......L...........................P........................ 120 
RSA/93/00       .I............N............................................. 120 
RSA/24/00       YL.....P......T............D................................ 120 
RSA/3/00        D.............................L.....IP...V...A..........T... 120 
RSA/17/00       ........................................T................... 120 
RSA/37/00       .S...........................S......TS.T.....T.............. 120 
                  *** * ******  ** **  ** * *  ****   * * *** **  ****** *** 
 
NL/1/94         TTQTTTEKKPTGATTKKETT-----RTTSTAATQTLNTTNQTSYVREATTTSARSRNSAT 175 
CAN75-98        .....A.....R....KETT-----..........L.......NGR...........N.. 175 
RSA/4/00        .....T.....G.I..KEKE---TT..........P.........K.......G...G.. 177 
RSA/29/00       ................KEKE---TT............................R...... 177 
RSA/90/00       ................KEKE---TT.........................I......... 177 
RSA/71/00       I...............KEKE---TT.........................T......... 177 
RSA/12/00       T...............KEKE---TT................................... 177 
RSA/23/00       ................KEKE---TT................................... 177 
RSA/54/00       ................KEKE---TT....................R.............. 177 
RSA/93/00       ................KEKEKETTT................................... 180 
RSA/24/00       ................KEKE---TT....I.........................K.... 177 
RSA/3/00        ................-EKE---TT....T.....L...................R..V. 176 
RSA/17/00       ................KEKE---TT................................... 177 
RSA/37/00       .......N......A.---E---TT..........P..............K...P..GA. 174 
                 **** * *** *  *         **** ***** *******   **** **   *  * 
 
NL/1/94         .QSSDQTTQAADPSSQPHHTQKSTTTTYNTDTSSPSS 212 
CAN75-98        ..S.............SQ.........H......... 212 
RSA/4/00        ..N....I.......KPH................... 214 
RSA/29/00       ..................................... 214 
RSA/90/00       ..................................... 214 
RSA/71/00       ..................................... 214 
RSA/12/00       ..................................... 214 
RSA/23/00       ...........................Y......... 214 
RSA/54/00       ............S..............H......L.. 214 
RSA/93/00       ............P........................ 217 
RSA/24/00       .......T...................Y......P.. 214 
RSA/3/00        .........T.....Q.Y................SN. 213 
RSA/17/00       ..................................... 214 
RSA/37/00       .R..........Q......................S. 211 
                *  **** * ** **   ********* ******  * 
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